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ABSTRACT 
Traditionally, prognostic information and selection of therapies for individuals with 
cancer is based on the results of studies that evaluate large groups of patients, in which there has 
been demonstrated a statistical benefit for the group. The success of this approach is directly 
related to the biological homogeneity of the chosen study group. Therefore, this approach is 
inherently sub-optimal for many individual patients, particularly in very heterogeneous disease 
entities such as diffuse large B-cell lymphoma (DLBL). However, with the recent introduction of 
high-throughput sequencing, it has become possible to extensively evaluate the biology of 
individual patient samples, which may eventually be used to transition to an era of true 
individualized management for cancer patients. Challenges to this approach include the 
complexity of the technology for clinical laboratories, high cost, and the immaturity of the 
databases analysis technology that are required to evaluate the results. Fortunately, rapid 
improvements continue to be made in all of these areas. The primary goal of this project was to 
explore the feasibility of creating “clinical-grade” evaluation methods toward developing 
personalized therapies in the near future. Clinical samples from patients with DLBL were used to 
examine the potential of two platforms, Oxford Nanopore and Illumina company products, for 
the analysis of complete mRNA transcriptomes since they can be representatives of intracellular 
biology. I found that the Illumina platform technique is feasible for the goal, while the Oxford 
Nanopore technology is not. Feasibility was further shown by successful use of the Illumina 
technology and the analysis method developed, to verify prediction of DLBL aggressiveness as 
previously determined by an alternate method, considered the “gold standard” in published 
literature. Finally, mRNA transcriptome data generated from pre-therapy diagnostic and post-
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therapy recurrence samples of DLBLs was used to demonstrate that it is feasible to use open-
source databases and programs to generate a list of therapeutic candidate proteins and pathways 
in each individual case. Although this feasibility study was carried out with only small number of 
patients, it shows that the components may finally be available to consider moving forward. 
However, further work is required to successful transition individualized tumor evaluation 
approaches into routine clinical practice.  
 
 
 
 
 
 
 
 
 
 
Keywords: 
 
 
Sequencing, Illumina, Oxford nanopore, Diffuse large B-cell lymphoma, DLBL, Whole 
transcriptome sequencing, Personalized medicine, Cancer.  
v 
 
Acknowledgment 
 
I would like to thank my Supervisor Dr. Hoyun Lee for his encouragement and constant 
support over the past two years. This thesis could not have been possible without his guidance, 
patience, and support. I would also like to thank my committee members: Dr. Rebecca McClure 
(Cosupervisor) and Dr. Kabwe Nkongolo. I would like to extend my special thanks to Dr. 
Rebecca McClure for sharing her knowledge, providing helpful advices, and for her exceptional 
support in writing, reviewing and editing this thesis.  
 
My special gratitude goes to Tyler Kirwan, who always provided valuable guidance and 
dedicated a lot of his time to teach me the techniques in RNA extraction, library preparation, 
sequencing, and data analysis. I want to specially thank him for his great help in data analysis 
using gnuplot 5.0. patchlevel 6 softwears to generate the heat maps.  
 
I would also like to thank my labmates: Dr. Indeewari Lindamulage, Dr. Vandana Srivastava, Dr. 
James Knockleby for their help in teaching me different lab techniques and sharing their 
expertise.  
vi 
 
Table of Contents  
 
ABSTRACT .................................................................................................................................. iii 
Acknowledgment ........................................................................................................................... v 
Table of Contents ......................................................................................................................... vi 
List of Tables ............................................................................................................................... vii 
List of Figures ............................................................................................................................. viii 
List of Abbreviations .................................................................................................................... x 
List of Appendices ........................................................................................................................ xi 
Introduction ................................................................................................................................... 1 
Methods .......................................................................................................................................... 7 
Results .......................................................................................................................................... 21 
Evaluation of the Oxford Nanopore-based RNAseq technique .......................................... 21 
RNAseq analysis using the TruSeq RNA Access library preparation technique and the 
Illumina NextSeq sequencer................................................................................................... 22 
Further Analysis...................................................................................................................... 28 
Discussion, Conclusion, and future work ................................................................................. 44 
Figures and legends .................................................................................................................... 50 
References .................................................................................................................................. 116 
Appendix A ................................................................................................................................ 116 
vii 
 
 
List of Tables 
Table 1: Read counts and genes expressed in 2 samples taken from the same patient (at 
diagnosis and after therapy relapse), each sample preserved in two different ways, 
fresh frozen and after formalin fixation with paraffin-embedding (FFPE). taken from 
the same patient, they differ only in the storage method. ............................................... 23 
Table 2: Clinicopathologic features associated with each pre-therapy sample. .................... 26 
Table 3: Some commonly altered gene in different samples. Green boxes show transcripts 
that were higher in the post-therapy samples. Red boxes show genes that were lower in 
the post-therapy samples. ................................................................................................... 29 
Table 4: Potential targeted therapies available for components of the cytokine pathway(s). 
mAb denotes monoclonal antibody. .................................................................................. 42 
Table 5: Sample 1 altered genes in the pathways identified by DAVID tool, and their 
expression in the recurrence tumor. .................................................................................. 97 
Table 6:  Sample 2, altered genes in the pathways identified by DAVID tool, and their 
expression in the recurrence tumor. ................................................................................ 101 
Table 7: Sample 3, altered genes in the pathways identified by DAVID tool, and their 
expression in the recurrence tumor. ................................................................................ 105 
Table 8: Sample 4, altered genes in the pathways identified by DAVID tool, and their 
expression in the recurrence tumor. ................................................................................ 109 
Table 9: Sample 5, altered genes in the pathways identified by DAVID tool, and their 
expression in the recurrence tumor. ................................................................................ 114 
viii 
 
List of Figures 
Figure 1: Oxford nanopore sequencing system. Error! Bookmark not defined. 
Figure 2a: Illumina Sequencing Technology workflow. 53 
Figure 2b: Illumina sequencing technology work flow.                                                           55 
Figure 3: Sequencing read preparation and normalization flow-chart, explained in detail in 
the methods section. 57 
Figure 4: RNAseq Illumina method evaluation using 2 samples stored as fresh frozen and 
FFPE. 59 
Figure 5: RNAseq full transcriptome analysis of 7 pre-treatment samples of DLBL. 61 
Figure 6a: (Shipp et al. Nature 2002;8;68) “cured & fatal/refractory” grouping.                63              
Figure 6b: RNA transcripts from genes listed in figure 6-a                                                     65              
Figure 7a: DLBL sample 1 - RNAseq full transcriptome heatmap.                                        67             
Figure 7b: DLBL sample 2 - RNAseq full transcriptome analysis heatmap.                         69               
Figure 7c: DLBL sample 3 - RNAseq full transcriptome analysis heatmap.                         71                
 
Figure 7d: DLBL sample 4 - RNAseq full transcriptome analysis heatmap.                         73                
 
Figure 7e: DLBL sample 5 - RNAseq full transcriptome analysis heatmap.                         75               
 
Figure 7f: DLBL sample 6 - RNAseq full transcriptome analysis heatmap.                          77                 
 
Figure 7g: DLBL sample 7 - RNAseq full transcriptome analysis heatmap.                         79                   
 
Figure 8a: DLBL sample 1 heat map showing gene expression that changed ≥ 5-fold 
between pre-and post-therapy samples.                                                                                     81                                              
 
Figure 8b: DLBL sample 2 heat map showing gene expression that changed ≥ 5-fold 
between pre-and post-therapy samples.                                                                                     83                                               
 
Figure 8c: DLBL sample 3 heat map showing gene expression that changed ≥ 5-fold 
between pre-and post-therapy samples.                                                                                     85                                          
 
ix 
 
Figure 8d: DLBL sample 4 heat map showing gene expression that changed ≥ 5-fold 
between pre-and post-therapy samples.                                                                                   87                                     
        
Figure 8e: DLBL sample 5 heat map showing gene expression that changed ≥ 5-fold 
between pre-and post-therapy samples.                                                                                   89                                             
 
Figure 8f: DLBL sample 6 heat map showing gene expression that changed ≥ 5-fold 
between pre-and post-therapy samples.                                                                                    91                                      
 
Figure 8g: DLBL sample 7 heat map showing gene expression that changed ≥ 5-fold 
between pre-and post-therapy samples.                                                                                    93                                     
 
Figure 9a: DLBL sample 1 – Pathway analysis screenshots.                                                  95               
Figure 9b: DLBL sample 2 – Pathway analysis screenshots.                                                  99                  
Figure 9c: DLBL sample 3 – Pathway analysis screenshots.                                                 103                 
Figure 9d: DLBL sample 4 – Pathway analysis screenshots.                                                107                     
Figure 9e: DLBL sample 5 – Pathway analysis screenshots.                                                 112  
 
 
 
 
 
 
 
 
 
x 
 
List of Abbreviations 
DLBL Diffuse Large B-cell Lymphoma 
OS Overall Survival 
GCB Germinal Center B-cell 
ABC Activated B-cell 
RNAseq RNA Sequencing 
FF Fresh Frozen 
FFPE Formalin Fixed Paraffin Embedded 
µM Micro Molar 
ml Milliliters 
s Second(s) 
rpm revolutions per minute 
min Minute(s) 
µl Microliter(s) 
°C Degree(s) in Celsius 
PCR Polymerase chain reaction 
ng Nano gram(s) 
mM Millimolar 
pM Picomolar 
ECM Extra Cellular Matrix 
  
xi 
 
List of Appendices 
 
 
Appendix A 120 
  
 
1 
 
Introduction 
Modern techniques for evaluating nucleic acids have clearly demonstrated that each 
human neoplasm is unique with respect to its genomic variation from normal, at the level of 
DNA sequence, RNA transcript levels, and expressed proteins in the cells. Within clinical 
medicine, however, neoplasms are "grouped" into diagnostic categories that have clinical 
relevance with respect to prognosis and selection of appropriate therapy. These groupings are 
typically based on what normal cell type the neoplastic cells most resemble, using a combination 
of features such as clinical signs and symptoms, body location, tissue involved, morphologic 
pattern, expressed proteins etc. More and more, nucleic acid biomarkers are being used to group 
neoplasms that are similar not only by the normal cell type that they are most closely resemble, 
but also by alterations in cell systems that give the neoplasms similar functional characteristics, 
as these are the features that will be most useful for predicting how the neoplasms will behave 
and respond to therapy. Typically, translational research studies use clinical diagnostic 
groupings, with the results of these studies (e.g. whether there is response to a certain drug) 
being evaluated based on whether there is a statistically significant difference between the group 
of interest and a selected "control group". The success of this approach is directly related to the 
homogeneity of the study group of neoplasms such that responses of individual neoplasms within 
these groups may not be identified, if they deviate from the response of the majority of samples 
in the group. This "grouping" approach has many other limitations and has clearly been more 
successful for some groups of neoplasms than others. However, this approach has been 
considered "the best we have" until very recently, when high-throughput sequencing 
technologies emerged and began making it possible to evaluate the components of multiple 
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cellular systems in great detail, simultaneously, for a cost that is approaching acceptability for 
routine clinical practice. It is these technologies that have allowed very rapid advances in our 
understanding of basic cell biology at the genomic level and also rapid progression of 
translational research that is now transforming all areas of medicine (particularly oncology) and 
ushering in the era of individualized, precision medicine.       
 
 In the field of oncology, one goal of individualized precision medicine would be to have 
"clinical grade" methods to rapidly evaluate many cellular processes of neoplastic cells upon 
initial patient presentation, such that the spectrum of oncogenic alterations that are unique to 
each patient's tumor could be identified and appropriate targeted therapy can be selected, or even 
rapidly designed. This approach would likely be most effective if simultaneous evaluation of the 
functional status of all of the proteins within the cell were performed; however, such technology 
for protein evaluation is not yet available. Evaluation of the RNA transcriptome may be the next 
most informative view of the status of intracellular systems, and advances in sequencing of RNA 
using high-throughput technology have resulted in methods that may finally be suitable for 
practical clinical use. High-throughput evaluation of DNA variants is least technically 
challenging and is already being used in limited capacity in oncology clinics, but DNA 
information is severely limited by a lack of knowledge regarding how DNA variants 
(individually, or in combination) ultimately affect the functioning of the proteome.      
 
One of the most challenging areas in oncology is selecting appropriate therapies for 
neoplasms specially those which are resistant to standard therapy or have recurred following 
standard therapy. Spear et al. reported that the percentage of cancer patients who actually 
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respond and benefit from the chemotherapy administrated to them is only 25% [1]. This alarming 
fact highlights the importance of moving cancer treatment towards more targeted personalized 
approach.  Diffuse large B-cell lymphoma (DLBL) is the most common type of non-Hodgkin 
lymphoma worldwide, representing 30%-40% of all newly diagnosed cases [2]. DLBL is an 
aggressive B-cell lymphoma, and it is relatively common in adults, with >50% being resistant to 
standard therapy or recurring following treatment with standard therapy [3]. Current standard 
therapy for DLBL patients is the regimen designated as R-CHOP (rituximab, cyclophosphamide, 
doxorubicin, vincristine, prednisone) [4]. None of the components in this therapy are tumor-
specific, with CHOP being a standard chemotherapy cocktail directed at any rapidly dividing 
cell, and rituximab being only a semi-specific therapy. Rituximab is an antibody targeting CD20, 
which is expressed in all B-cells, with no discrimination between normal and neoplastic B-cells. 
The current diagnostic category of DLBL is known to be biologically a very heterogeneous 
group of neoplasms and many biomarkers have been evaluated for their usefulness in clinically 
relevant subclassification, with minimal success. As such, no neoplasm-specific genomic 
biomarkers are currently being used as clinical therapeutics and only small numbers have shown 
utility even for prognostic stratification within this large group. The latter include increased 
expression of MYC +/- BCL2 and/or BCL6 at the level of protein detection and IGH/MYC +/- 
IGH/BCL2 and/or IGH/BCL6 at the level of DNA detection [5]. For a long time DLBL was 
considered as one disease until the early 2000s, when it was shown that RNA expression 
profiling had utility for stratifying DLBLs into at least 2 sub-groups with respect to overall 
survival (OS). Alizadeh et al.[6] used oligonucleotide capture array technology to evaluate 
selected RNA transcripts and identified one group resembling normal germinal center B-cells 
(GCB-type) and a second group resembling blood B-cells that had undergone in-vitro activation 
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(activated B-cell (ABC)-type). The GCB-type group had a statistically better OS (76%) than the 
ABC-type group (16%). Similarly, Shipp et al.[7] evaluated RNA transcripts in DLBL by 
capturing a different selected set of RNA transcripts (also used oligonucleotide arrays) and 
identified one group with excellent OS (“cured” group - 70% 5 year OS) and a second group 
with poor OS (“Fatal/Refractory” group -12% 5 year OS).   
However, because gene expression profiling has proved to be technically challenging and poorly 
reproducible in the clinical setting, this type of analysis is not currently used for prognostication 
of DLBL. Instead, a less-than-optimal surrogate assay is used that includes immunoperoxidase 
staining of tissue sections to evaluate the expression of 3-6 proteins, and several elaborate 
interpretation algorithms aimed at achieving “best sensitivity and specificity” for predicting the 
category that would be obtained using gene expression profiling to separate DLBL into the “cell 
of origin” groups identified by Alizadeh et al.[6] After years of using this prognostication 
method in the clinical setting, it has become clear that it is not very reliable; e.g. the GCB 
phenotype group (good prognostic feature) actually contains some of the most aggressive DLBLs 
with the poorest survivals, re-emphasizing how conclusions made from analysis of groupings of 
heterogeneous neoplasms do not translate well for individual patients.     
   
 It is clear that better “clinical-grade” techniques and approaches are needed for optimal 
management of patients with DLBL and there is particular interest in determining whether the 
concept of real-time individualized tumor evaluation at the genomic level is feasible and could 
provide for a truly individualized diagnostic, prognostic, and therapeutic approach for these 
patients. This approach may have particular impact for patients with neoplasms that are resistant 
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to current therapy or recur following initially successful therapy. Challenges to personalized 
genomic evaluation of neoplasm, including DLBL, have been many: 
1.   Techniques for extensively multiplexed evaluation of macromolecules (DNA, RNA, 
protein) have not been available until recently.  
2.   As techniques for extensively multiplexed evaluation of macromolecules have emerged, 
they have still not been suitable for clinical use due to one or more of the followings: too 
complicated to execute protocols in a clinical lab; data obtained are not reliable or 
sufficiently reproducible; require too much clinical materials; not compatible with the 
types of clinical materials typically obtained in clinical work (e.g. paraffin-embedded); 
required too much materials for the amounts obtainable during clinical work-ups; and/or 
too costly for routine uses.    
3.   Insufficient knowledge of “systems biology” such that cellular components being 
identified as having variations in evaluation of neoplasms, are frequently of unknown 
function. In addition, there has not been easy access to what knowledge there is.    
4.   Insufficient knowledge and databases containing information regarding currently 
available or potential directed therapeutics.   
 
 In the last few years, however, there has been substantial improvement in all of the 
challenging aspects mentioned above. Thus, it is now starting to be conceivable that an 
individualized, genomic approach to evaluate patients with neoplasms, such as DLBL, may be 
possible. In particular, high-throughput methods for RNA transcriptome analysis (RNAseq) are 
particularly attractive to explore. Of course, cellular protein analysis would likely be the best 
representation of cellular functional states; however, it is not yet amenable.  
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 Based on this reasoning, the goals of this project were set as follows: 
1) Test two very recently developed methods for transcriptome analysis using high-throughput 
sequencing (RNAseq) to see if either of these methods is feasible to use in a clinical setting at 
reasonable cost; i.e. are they "clinical-grade" with respect to adequacy for use on routine clinical 
samples (including paraffin-embedded tissue)?  
2) Evaluate the preferred RNAseq method for its ability to produce data that can correctly sub-
classify DLBL samples into two separate categories that have clinical relevance for prognosis as 
previously demonstrated using capture array technology.  
3) Provide preliminary "proof of feasibility" for the use of RNAseq as a method for identifying 
proteins and/or intracellular pathways that could be candidates for individualized therapy in the 
clinical setting. This will be done using DLBL samples taken from patients at the time of 
diagnosis and at post-therapy recurrence, to identify RNA transcripts that show a significant 
change in expression level post-therapy. Currently available software tools and databases will 
then be used to identify which cellular pathways contain the predicted altered proteins and 
investigate whether any of the components or pathways would be amenable to targeted therapy 
using currently available therapeutics.     
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Methods 
RNA extraction from clinical samples 
 
Waste tissue from patients with DLBL was obtained from the Health Sciences North 
clinical laboratory. Both freshly frozen (FF) and formalin-fixed, paraffin-embedded (FFPE) 
tissues were used. From each patient, RNA was extracted from at least one sample taken at the 
time of diagnosis and from at least one sample taken at the time of recurrence. All patients had 
received the same standard chemotherapy for DLBL: R-CHOP. RNA was extracted using the 
AllPrep® DNA/RNA FFPE kit (www.qiagen.com), all kit buffers and reagents were used as per 
the manufacturer's instructions as following: For frozen tissue, excised tumor was disrupted 
using a mortorized mortar and pestle in lysis buffer and then homogenized using a Qiashredder 
column, prior to RNA extraction. For FFPE samples, areas of tumor were excised and cut into 
10-20 µm thick sections using a scalpel. These sections were placed in a 1.5 ml microcentrifuge 
tube and deparaffinized by adding 1 ml xylene, vortexed vigorously for 10 s, and spun at full 
speed (17,000 rpm) in Eppendorf 5415 microcentrifuge for 2 min. (Note: unless specified 
otherwise, all centrifugations ("spins") were performed at highest speed in Eppendorf 5415 
microcentrifuge for 1.5 ml tubes, or BIO-RAD low-speed mini centrifuge for .2 ml PCR tubes). 
The supernatant was removed; 1 ml of 100% ethanol was added to the pellet to remove residual 
xylene; the sample was vortexed; and finally, the pellet was spun for 2 min. The supernatant was 
removed and discarded. With the lid open, the tube was incubated for 10 min at room 
temperature to eliminate residual ethanol. The pellet was resuspended in 150 µl of buffer PKD, 
and the tube inverted several times to loosen the pellet. 10 µl of proteinase K was added and 
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mixed by vortexing, followed by incubation for 15 min at 56°C, and then chilled on ice for 3 
min. The sample then was spun for 15 min, and the supernatant (containing the RNA) was 
transferred into a new 1.5 ml tube, followed by incubation for 15 min at 80°C. Finally, sample 
was collected after a quick spin.  
 For RNA clean-up, RNeasy MinElute spin column (www.qiagen.com) was used as 
suggested by the manufacturer (buffers and reagents supplied in the kit used as per the 
manufacturer's instructions). Briefly, 320 µl of buffer RLT was added to RNA and mixed by 
vortexing. 720 µl of 100% ethanol was added and mixed by vortexing. 700 µl of the sample was 
then transferred to a spin column setting on a 2ml collection tube, and spun for 15 s. The eluate 
was discarded and the same column was used again as above until the entire RNA sample had 
been passed through it. The column was given a final wash with 350 µl of FRN buffer, and the 
final eluate discarded. 10 µl of prepared DNase I stock solution (Dissolved lyophilized DNase I 
(1500 Kunitz units, provided in the kit) in 550 µl of the RNase-free water) was mixed with 70 µl 
of RDD buffer by gently inverting the tube. The mixture was directly transferred to the column, 
incubated at room temperature for 15 min, and then 500 µl of FRN buffer was added to the 
mixture in the column and spun for 15 s. The eluate (containing RNA) was transferred into a 
fresh spin column placed at the top of a new 2 ml collection tube, spun for 15 s, and the eluate 
was discarded. 500 µl of buffer RPE was added to the column, and spun again, this step was 
repeated twice and the eluate was discarded. The column was then placed in a new collection 
tube and spun for 5 min. Then the column was placed on 1.5 ml collection tube, 30 µl of RNase-
free water added, and RNA was eluted by spinning for 1 min. The extracted total RNA 
concentration was measured using Nanodrop (www.thermofisher.com) and stored at -80°C.  
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Synthesis of cDNA from the extracted RNA for RNase P experiment, by using 
Superscript™ IV First-Strand Synthesis System (www.thermofisher.com) 
 
To get a total of 20 µl reaction volume, 500 ng of total RNA extract was used for reverse 
transcription. RNA primer mix was prepared in a small 0.2 ml PCR tube as follow: 50 ng/µl of 
random hexamers, 10 mM dNTP mix, 500 ng of template RNA, and up to 13 µl of DEPC-treated 
water were mixed and briefly centrifuged, then heated at 65°C for 5 min. The tubes were then 
incubated on ice for >1 min. While incubating, RT reaction mix was prepared in a new 0.2 ml 
tube by combining 5× SSIV buffer (provided in the kit), 100 mM DTT, and 40 units/µl 
ribonuclease inhibitor. The contents were mixed, spun briefly, and then added to the RNA primer 
mix. The reaction mix was incubated at 23°C for 10 min and then at 50°C for 10 min. The 
reaction was stopped by incubating at 80°C for 10min. cDNA concentration was measured using 
Nanodrop (www.thermofisher.com). 
 
Test the quality of extracted RNA by TaqMan RNase P Detection Reagents kit 
(www.thermofisher.com)  
 
To ensure the accuracy of sequencing results, cDNA must be accurately quantified before 
a sequencing library preparation. RPP25 (a.k.a. RNaseP) is a single copy gene that can be used 
to accurately quantify amplifiable cDNA or DNA in a sample by comparing it to a standard 
curve prepared from a sample of known DNA concentration.  
Seven tubes of standard DNA serial dilutions were prepared in duplicate, with 
concentrations of 5, 2.5, 1.25, 0.625, 0.3125, 0.15625 and 0.078125 ng/µl. A dilution of 1:100 
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ratio of sample cDNA was also prepared in nuclease-free water in duplicate. PCR master mix 
was prepared by combining the following volumes of reagents per reaction: 10 µl of TaqMan 
Universal PCR Master Mix (2×) or 20 µl of 1× (AmpliTaq Gold® DNA Polymerase, UP (Ultra 
Pure), Uracil-­‐N glycosylase (UNG), dNTPs with dUTP, ROX™ Passive Reference, and 
optimized buffer components), 1 µl of 20× RNase P Primer-Probe mix, and 6.5 µl of nuclease-
free water. In a 96 well PCR plate, 17.5 µl of the master mix was added to each well. 2.5 µl of 
each control DNA dilution were added to “standard” wells. 2.5 µl of sample cDNA dilution was 
added to each sample well. 2.5 µl of Nuclease-free water was added to negative control wells. 
Each standard, sample cDNA and negative control were in duplicate. The plate was sealed with a 
sheet of MicroAmp Optical Adhesive film (Thermo Fisher), centrifuged to ensure all liquid was 
at the bottom of each well and loaded on a real-time, quantitative PCR machine (Applied 
Biosystems 7900). Sample cDNA concentrations were determined by comparing to the results of 
the standard curve DNA samples. Nonamplifiable or poorly amplifiable samples were excluded 
from further experiments. 
 
RNAseq Method #1 (Nanopore Technologies) 
 
The first RNAseq method examined was the commercial platform marketed by Oxford 
Nanopore Technologies (Oxford, UK). This is considered a 3rd generation high-throughput 
sequencing system and it is a technique that became available in 2015. It has theoretical 
advantage over previous methods that would make it an attractive choice for a clinical-grade 
assay method: Full length RNA sequencing can be performed without fragmentation or initial 
PCR amplification to create a library, allowing for identification of individual mRNA isoforms; 
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RNA or cDNA are sequenced directly without intermediate amplification by PCR or branching 
chain, processes that increase technical complexity and potential errors;  no large equipment is 
needed as sequencing is carried out within an array resembling a data-stick and analyzed directly 
via consumable that is inserted into any computer; rapid processing time (<24 hours vs 3-7 days 
for second generation sequencing systems). The Oxford Nanopore technology is diagramed in 
(Figure. 1) and the experiment was performed as per manufacturer's instructions.  
 
RNAseq Method #2 (Illumina) 
 
In the fall of 2016, the Illumina sequencer company (illumina.com) released a method 
called TruSeq RNA Access Library Prep. It allows the evaluation of the entire transcriptome 
utilizing a standard Illumina technology (second generation sequencing technology), using either 
fresh or FFPE samples. Importantly, it is amenable with small amounts of RNA typically 
obtained from clinical samples as it requires only 10-100 ng of RNA. It also can sequence up to 
4 samples simultaneously on a single flow cell, which makes the technology cost-effective. This 
was the first method available for either of the standard high-throughput sequencing machines 
typically available in clinical laboratories that appeared suitable for the goals of this project (the 
other is Ion Torrent by Thermo Fisher Scientific). The Illumina sequencing workflow is 
diagramed in (Figure. 2: a, b) and the library preparation method which includes the conversion 
of RNA to DNA is described below. 
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Sequencing Library Preparation using TruSeq RNA Access Library Prep kit (all the 
reagents and buffers used are supplied in the kit, Illumina USA, except AMPure XP beads: 
Beckman Coulter Canada: A63881, AMPure XP, 60 mL) 
 
20 ng of total RNA, if isolated from freshly frozen tissue and 100 ng of RNA, if isolated 
from FFPE tissue were used to prepare the libraries. RNA was diluted in nuclease-free water to a 
volume of 8.5 µl in a 0.2 ml PCR tube, and 8.5 µl of Elute prime fragment high concentration 
mix added to the RNA. First strand cDNA was synthesized by adding 8 µl of the FIRST 
STRAND Synthesis Act D + superscript II mix, and thoroughly mixed by vortexing, followed by 
a quick spin. The sample was then subjected to cDNA synthesis in the thermocycler, as follows: 
25°C for 10 min, 42°C for 15 min, 70°C for 15 min, and then held steadily at 4°C. Second strand 
cDNA was synthesized by adding 5 µl of resuspension buffer and 20 µl of Second Strand 
Marking Mix followed by vortexing and a quick spin. The sample was then incubated in the 
thermocycler at 16°C for 1 h, followed by steadily holding at 25°C. 
 
AMPure XP clean up (Beckman Coulter Canada: A63881, AMPure XP, 60 mL): 
After generating double stranded DNA, 90 µl of Ampure XP beads was added to it and 
incubated at room temperature for 5 min, briefly spun, and the tube was positioned on a magnetic 
stand to precipitate the Ampure beads (magnetic beads). Once the solution was cleared, 
supernatant was discarded. 200 µl of 80% ethanol was added to wash the sample then the tube 
was moved back and forth between adjacent wells of the magnetic stand to move the bead pellet 
within the tubes, the ethanol wash step was repeated twice. The sample was incubated at room 
temperature for up to 5 min on nonmagnetic stand to evaporate the remaining ethanol, after 
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which 17.5 µl of resuspension buffer was added, followed by thorough mixing and incubation at 
room temperature for 5 min. The sample was briefly spun, and then positioned again on the 
magnetic stand. Once solution was cleared, 15 µl of supernatant was transferred to a new 0.2 ml 
PCR tube. At this point, the sample could be safely stored at -20 °C for up to 7 days. 
 
Adenylate 3’ Ends: 
2.5 µl of resuspension buffer was added to the 15 µl sample prepared as above. After 
12.5 µl of A-Tailing mix was added, the sample mixed well by briefly vortexing it, followed by 
quick spin and then incubated in the thermocycler at 37°C for 30 min, 70 °C for 5 min, then held 
steadily at 4 °C. 
 
Ligate Adapters: 
2.5 µl of ligation mix was added to a 30-µl sample prepared as above. After 2.5 µl of one 
unique RNA Adapter index (barcode) was added, the sample was mixed thoroughly, briefly 
spun, and then incubated in the thermocycler at 30°C for 10 min. 5 µl of kit Stop ligation buffer 
was added immediately, the sample mixed thoroughly, and briefly spun. The sample was then 
subjected to two Ampure XP clean up procedures as previously described in Ampure XP clean 
up section (page12).  
 
First PCR Amplification: 
5 µl of PCR Primer cocktail was added to a 20-µl sample prepared as above, followed by 
addition of 25 µl PCR master mix, mixed thoroughly, briefly spun, and PCR amplified using the 
following conditions: 98°C for 30 s, 15 cycles of 98°C for 10 s, 60°C for 30 s, 72°C for 30 s, 
14 
 
72°C for 5 min, then finally held steadily at 4°C. The PCR product was cleaned up using 
Ampure XP beads as described above in Ampure XP clean up section (page12). At this point, 
sample can be stored safely at -20°C for up to 7 days. 
 
Validation and pooling of libraries: 
Each DNA library created as described above was quantified using the nanodrop. 200 ng 
of each library was then combined to run on the same flow cell (4 samples/ flow cell). The 
volume was brought up to 45 µl with resuspension buffer to complete the pooled library mix.  
 
First Hybridization:  
50 µl of Capture Target Buffer 3, and 5 µl of Coding Exome Oligos were added to 45 µl 
library mix and mixed thoroughly. The tube was incubated in the thermocycler as follows: 95°C 
for 10 min, and then incubation for 1 min at gradually lower temperature of 92°C, 89°C, 86°C, 
82°C, 80°C, 78°C, 76°C, 74°C, 72°C, 70°C, 68°C, 66°C, 64°C, 62°C, and 60°C then held at 
58°C. Once the temperature reached 58°C, the sample was incubated at that temperature for 1.5 
h, immediately followed by First Capture (below) to prevent the sample from cooling down 
(which could result in non-specific binding). 
 
First Capture: 
The entire 50 µl of the first hybridization PCR reaction described above was mixed and 
transferred into a 1.5 ml microtube. 250 µl of Streptavidin Magnetic Beads was added into the 
sample, vortexed thoroughly, and then incubated for 30 min with occasionally vortexing it to 
keep the beads suspended. The sample was placed on a magnetic stand and incubated until the 
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liquid was clear, and then the supernatant was removed and discarded. The beads were 
resuspended in 200 µl of Enrichment Wash Solution and incubated at 50°C for 20 min. The 
sample was placed on a magnetic stand, the solution allowed to clear, and the supernatant was 
discarded. A second wash was performed using the Enrichment Wash Solution following the 
same steps. During the second 50°C incubation, Elution Pre-Mix was prepared by combining 
28.5 µl of Enrichment Elution Buffer1 and 1.5 µl of 2N NaOH (HP3). Once the supernatant was 
removed after the second wash, 23 µl of Elution Pre-Mix was added to the isolated beads, 
vortexed thoroughly, and incubated for 2 min. The sample then was placed on the magnetic stand 
until the solution cleared and 21 µl of the supernatant was transferred to a new 0.2 ml PCR tube, 
and 4 µl of Elute Target Buffer 2 was added.  At this point, sample could be stored at -20°C for 
up to 7 days. 
 
Second Hybridization: 
20 µl of resuspension buffer was added to the 25 µl sample prepared by the first 
hybridization and the first capture step procedures. 50 µl of Capture Target Buffer 3, and 5 µl of 
Coding Exome Oligos were added to 45 µl library mix and mixed thoroughly. The tube was 
incubated in the thermocycler as follows: 95°C for 10 min, and then incubated for 1 min at 
gradually lower temperatures of 92°C, 89°C, 86°C, 82°C, 80°C, 78°C, 76°C, 74°C, 72°C, 70°C, 
68°C, 66°C, 64°C, 62°C, and 60°C then held at 58°C. Once the temperature reached 58°C, the 
sample was incubated at that temperature for 1.5 h, immediately followed by second Capture 
(below) to prevent the sample from cooling down (which could result in non-specific binding). 
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Second Capture: 
The entire 50 µl of the second hybridization PCR reaction described above was mixed 
and transferred into a 1.5 ml microtube. 250 µl of Streptavidin Magnetic Beads was added into 
the sample, vortexed thoroughly, and then incubated for 30 min with occasionally vortexing it to 
keep the beads suspended. The sample was placed on a magnetic stand and incubated until the 
liquid was clear, and then the supernatant was removed and discarded. The beads were 
resuspended in 200 µl of Enrichment Wash Solution and incubated at 50°C for 20 min. The 
sample was placed on a magnetic stand, the solution allowed to clear, and the supernatant was 
discarded. A second wash was performed using the Enrichment Wash Solution following the 
same steps. During the second 50°C incubation, Elution Pre-Mix was prepared by combining 
28.5 µl of Enrichment Elution Buffer1 and 1.5 µl of 2N NaOH (HP3). Once the supernatant was 
removed after the second wash, 23 µl of Elution Pre-Mix was added to the isolated beads, 
vortexed thoroughly, and incubated for 2 min. The sample was placed on the magnetic stand 
until the solution cleared and 21 µl of the supernatant was transferred to a new 0.2 ml PCR tube, 
and 4 µl of Elute Target Buffer 2 was added.  At this point, sample could be stored at -20°C for 
up to 7 days. 
 
Capture Sample Clean-up with AMPure XP Beads: 
Capture sample clean-up was done with AMpure XP beads as described previously in 
Ampure XP clean up section (page12), followed by a second PCR Amplification. 5 µl of PCR 
Primer Cocktail, 20 µl of Enhanced PCR Mix were added to the sample, and the DNA was 
amplified as follows: 98°C for 30 s, 10 cycles amplification at 98°C for 10 s, 60°C for 30 s, 72°C 
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for 30 s, and 72°C for 5 min, followed by incubation at 10°C. AMpure XP Beads clean-up was 
performed as previously described in Ampure XP clean up section (page12). 
 
Validating the Final Library: 
Quantification was performed using KAPA biosystem quantification kit 
(www.kapabiosystems.com) following the manufacturer's instructions, which was further 
confirmed by agarose gel electrophoresis. 
 
Denature and dilute libraries: 
40 µl of 0.5 nM library was mixed with 40 µl of 0.2 N NaOH, mixed well and 
centrifuged at 280 ×g for 1 min. The sample was then incubated for 5 min at room temperature to 
denature double stranded DNA into single strands. 40 µl of 200 mM Tris-HCl, pH 7 was added, 
mixed, and centrifuged at 280 ×g for 1 min. The sample was diluted to 20 pM concentration by 
adding 881 µl of prechilled HT1, mixed and centrifuged at 280 ×g for 1 min. The sample was 
then further diluted to loading concentration of 1.8 pM in 1.3 ml volume by adding 117 µl, 1183 
µl of denatured library, and prechilled HT1 respectively. The sample was placed on ice until 
used.  Illumina NextSeq instrument, NextSeq Platform version NCS v1.3 was used for 
sequencing.  
 
Conversion of raw RNAseq data into normalized levels of gene expression to generate RNA 
expression “heat-maps” (Figure 3).  
Illumina sequenced reads were aligned to the reference human genome (hg19) using the 
RNA-Seq Alignment Application on Basespace (Illumina Inc.) (STAR aligner algorithm). This 
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program produces aligned raw reads in the form of bam file format and flags individual reads as 
properly aligned, low quality, or ambiguous (location cannot be determined because sequence is 
present in multiple regions of the genome). Reads that were not classified as properly aligned 
were filtered out. The nature of this library preparation method can cause certain sequence to be 
overrepresented in the sequencing library simply because they are amplified more efficiently by 
PCR than others, due to a variety of reasons including differences in length, GC content, and 
other factors. In order to prevent these kind of PCR artifacts from influencing downstream 
analysis, all reads that were identified by the STAR aligner as PCR duplicates (having identical 
length, sequence and mapping location as another properly aligning read) were removed from 
subsequent analysis. The number of unique, properly aligned reads mapping to each gene were 
calculated and expressed as raw read counts per gene for each sample.  
 Raw read counts for each gene within a patient sample were filtered by applying a 
minimum read threshold of 1 read, which removes all genes without at least 1 read from the 
analysis. A minimum read threshold of 20 was then applied to each set of paired samples to 
remove any genes that did not have a minimum of 20 reads in either the initial sample or the 
recurrence sample. Genes with raw read counts below either of these empirically defined 
thresholds were considered unreliable and removed from analysis for that sample pair. Raw read 
counts were then normalized to the number of transcripts from the control gene ABL1, to allow 
comparison of relative gene expression across samples. ABL1 has previously been shown to be 
an excellent "house-keeping" gene in lymphoid cells, producing a stable level of transcripts in all 
cells under a variety of different conditions, and is suitable for this type of normalization[8]. 
Genes within a pair of samples that had absolute fold greater than the threshold of the minimum 
fold-changes were determined to be differentially expressed. RNA sequencing data has been 
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shown to be heteroscedastic, meaning that genes whose read counts differ by orders of 
magnitude are also expected to have different variances. If not accounted for, this can lead to an 
increase in Type 1 error. Since the minimal amount of tissue available prevented the use of 
biological replicates in this study, statistical methods to normalize for variances could not be 
used. Instead, any differential expression between samples that occurred outside of the two 
orders of magnitude range from the normalized control gene were considered to be unreliable 
and filtered out. Hierarchical clustering using Euclidean distance as the similarity measure was 
performed on the remaining differentially-expressed genes (R version 3.0.2 hclust command). 
Finally, “Heatmaps” were generated using gnuplot 5.0, patchlevel 6. 
 
Analysis of RNAseq data to assign pre-treatment samples to previously identified, RNA 
expression-based prognostic categories. 
Sequencing data reads for individual samples were normalized to ABL1 RNA transcripts: 
(# of reads per specific gene) × 1000/(# of ABL1 reads in that sample).  Since this analysis 
compares relative amounts of different genes within the same sample, transcript length had to be 
taken into account:  normalized reads / (size of specific gene in kb). The scale was colored to 
match that of  Shipp et al.[7] (Figure 6a) with lower expression in black, and higher expression 
in red.  
	  
Analysis of RNA expression levels for potential therapeutic target proteins and cellular 
pathways. 
DAVID bioinformatics database 6.8 (https://david.ncifcrf.gov/), and Panther 
classification system (http://pantherdb.org/) were used to identify the genes that are common in a 
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certain pathway and their biological functions respectively. These databases require the entry of 
a list of genes. The list of genes generated for each sample with ≥ 5-fold change (≥ 5×)	  was 
entered and the results were analyzed. The KEGG_PATHWAY grouping of genes was chosen 
over other options available by tools in the DAVID system. The results show only the 
significant, or strongly significant, pathways. DAVID tool uses EASE Score (a modified Fisher 
Exact P-Value) for gene-enrichment analysis. Panther tool determine p-value by the binomial 
statistic.  
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Results  
 
Evaluation of the Oxford Nanopore-based RNAseq technique 
High quality RNA from the CCRF-CEM cell line was used for a pilot study to examine 
the feasibility of using the Oxford Nanopore technology for my study. Unfortunately, this 
technology appeared unable to provide data that would achieve the project’s objectives, with the 
following limitations observed:  
•   Very low throughput compared to 2nd generation sequencing technologies. 
•   High error rate.  
•   High cost per read.	  
•   Inadequate software support to help analyzing the data generated. 
Thus, even using high quality RNA from a well-known cell line (it would be worse for actual 
patient samples, particularly FFPE), it appeared that this system was unlikely going to be 
adequate for generating “clinical grade” data. Therefore, I decided that it was not worthwhile 
continuing to test the Nanopore technology for the purposes of this project. It was approximately 
at this time that the RNAseq method #2 for the Illumina sequencing platform became available. 
Therefore, I examined the feasibility of this platform, as described in the Materials and Methods 
section. 
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RNAseq analysis using the TruSeq RNA Access library preparation technique and 
the Illumina NextSeq sequencer. 
As a pilot study, the sequencing method was evaluated by testing two samples of DLBL 
for which both FF and FFPE materials were available. I examined each sample from both storage 
methods separately. This was important because most clinical samples are FFPE, and this storage 
method does not include a nuclease inhibitor which cause the DNA and RNA to get degraded 
over a long time of storage. Table 1 shows data regarding reads and genes expressed for the two 
sample pairs following data clean-up and normalization. 
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Sample 1 (at diagnosis)  Fresh frozen FFPE 
Number of raw reads 1,943,628 3,388,558 
Number of expressed genes detected 14,980 14,655 
Number of concordant genes 13,698 
Number of unique genes 1,282 957 
Sample 2 (at recurrence) Fresh frozen FFPE 
Number of raw reads 7,451,942 4,430,964 
Number of expressed genes detected 15,547 14,800 
Number of concordant genes 14,179 
Number of unique genes 1,368 621 
Table 1: Read counts and genes expressed in 2 samples taken from same patients (at diagnosis 
and after therapy relapse), each sample preserved in two different ways, fresh frozen and after 
formalin fixation with paraffin-embedding (FFPE). 
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Very similar numbers of expressed genes were detected in the samples and the number of 
concordant genes were also very close to the numbers of detected genes. The presence of unique 
genes is expected and can be due to the presence of different tumor clones or different amounts 
of normal cells in different samples. These results confirmed that the RNAseq process had been 
technically successful. The normalized gene expression data for the entire transcriptome in the 
samples are shown in (Figure 4). The reproducibility of the expressed genes and concordant 
genes on the same samples (see also heat map patterns in figure 4) appeared excellent based on 
the expected intra-sample variation for the RNAseq technique in general. This conclusion was 
further supported by a comparison of the gene expression profile of each tumor evaluated, which 
demonstrated a tumor-specific profile that was recognizable for each sample from the others 
(Figure 5).  
 
I then evaluated the technique’s ability to align each sample with one of the 2 prognostic 
categories identified by Shipp et al.[7]: "cured" group or "fatal/refractory" group (Figure 6a). 
Since it was known that all neoplasms tested were clinically aggressive, in that they were 
refractory to therapy or recurred following R-CHOP therapy, it was expected that this analysis, if 
successful, should clearly align each neoplasm into the "fatal/refractory" group. The results of 
this analysis are shown in (Figure 6b). Despite the restricted RNA transcript set available for the 
analysis (see Methods), each pre-therapy DLBL sample did align with the transcript levels and 
patterns as expected for the "fatal/refractory" group. The clinical features corresponding to each 
pre-therapy DLBL sample are shown in Table 2.  
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Currently used clinical prognostic markers for DLBL are reflected in Table 2, as 
available. These include an immunoperoxidase stain panel that evaluates expressed proteins to 
determine prognosis per the Hans’ algorithm, in which DLBL of germinal center B-cell type 
(GCB) are considered to have better prognosis than DLBL of non-germinal center type (NGC). 
Additional prognostic information is obtained by evaluating protein expression of both MYC and 
BCL2 by immunperoxidase staining, with double-expressers considered to have a very poor 
prognosis. Finally, evaluation of MYC, BCL2 and BCL6 at the DNA level is typically done using 
fluorescence in-situ hybridization (FISH). Disruption of MYC (typically indicating a IG/MYC 
translocation) is a poor prognostic feature and disrupted MYC with either disrupted BCL2 or 
BCL6 are considered to have an even worse prognosis (aka “double hit lymphomas”) [5].  Table 
2 shows that some DLBL considered in the “good prognosis” GCB category by Hans’ algorithm 
or that showed no indication of MYC disruption, were actually clinically aggressive, re-
emphasizing the fact that studies of groupings of heterogeneous neoplasms do not translate well 
for individual patients. 
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Table 2: Clinicopathologic features associated with each pre-therapy sample. 
27 
 
 
  
 Sampling at 
diagnosis 
 time to post-therapy 
sample 
Sample 1 (1387) DLBL 
(de-novo) 
GCB by Hans’ 
algorithm 
No MYC disruption 
No MYC IHC done 
43 months 
Sample 2 (6100)  
DLBL 
(de-novo) 
 
 
NGC by Hans’ 
algorithm 
No MYC disruption 
MYC IHC positive 
 
 
26 months 
 
Sample 3 (1009)  
DLBL 
(transformed from 
low-grade) 
 
 
GCB by Hans’ 
algorithm 
No MYC evaluation 
 
 
25 months 
 
Sample 4 (2093)  
DLBL 
(de-novo) 
 
 
GCB by Hans’ 
algorithm 
No MYC evaluation 
 
 
11 months 
 
Sample 5 (706)  
DLBL 
(de-novo) 
 
 
GCB by Hans’ 
algorithm 
No MYC disruption 
MYC IHC not done 
 
 
10 months 
 
Sample 6 (13084)  
DLBL 
(de-novo) 
 
 
NGC by Hans’ 
algorithm 
No MYC disruption 
evaluation 
MYC IHC positive 
 
 
6 months 
 
Sample 7 (948)  
DLBL 
(transformed from 
low-grade) 
 
 
NGC by Hans’ 
algorithm 
No MYC disruption 
MYC IHC positive 
 
 
26 months 
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Further Analysis 
Next, I examined pre- and post-therapy samples, FFPE (8 samples) and FF (2 samples) 
tumor sample pairs from 10 patients using the method described above. Unfortunately, RNA 
recovery on at least one of the samples in 3 of the pairs of FFPE was too poor for sequencing, 
leaving complete results on only 7 sample pairs. Transcriptome profile heat-maps for these 7 
sample pairs are shown in (Figure 7a-g).  
To narrow down the pool of potential targetable proteins, the data was analyzed to 
identify RNA transcripts, for which expression levels had changed by ≥ 5 times (called ≥ 5× 
group) between the samples at diagnosis and post-therapy relapse stages (Figures 8a-g). Genes 
represented in the ≥ 5× group were further evaluated for potential biological functions in the 
context of cellular pathways using both Panther Classification System tool (www.pantherb.org) 
and David Functional Annotation Tool (https://david.ncifcrf.gov). A summary of the findings is 
presented in simplified form in Table 3. Representative screenshots of the types of results 
obtained from the DLBL cases are shown in Figures 9a-d. Two of the samples (6 and 7) did not 
have a sufficient number of genes identified in the ≥ 5× group to process through the two 
analysis tools and therefore were not subjected to these algorithm-based analyses.  
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Table 3: Some commonly altered gene in different samples. Green boxes show transcripts that 
were higher in the post-therapy samples. Red boxes show genes that were lower in the post-
therapy samples. 
30 
 
 
  
Gene sample)1 sample)2 sample)3 sample)4 sample)5 )sample)6 )sample)7
ATRNL1 H)in)REC H)in)REC
BGN H)in)REC L)in)REC
C4A H)in)REC L)in)REC
CCL19 H)in)REC L)in)REC
CD6 L)in)REC L)in)REC
CDT1 H)in)REC H)in)REC
CHIT1 L)in)REC L)in)REC L)in)REC
COL12A1 H)in)REC L)in)REC H)in)REC
COL15A1 L)in)REC L)in)REC
COL6A1 H)in)REC L)in)REC
COLEC12 H)in)REC H)in)REC
CTB?113P19.1 H)in)REC L)in)REC
F5 H)in)REC L)in)REC
FDCSP L)in)REC L)in)REC
HTR3A H)in)REC L)in)REC H)in)REC
JCHAIN H)in)REC L)in)REC
LOC100507388 H)in)REC L)in)REC
POSTN H)in)REC L)in)REC H)in)REC
PVRL1 H)in)REC H)in)REC
SULF1 L)in)REC H)in)REC
THBS1 L)in)REC H)in)REC
TNC H)in)REC L)in)REC
CSMD1 L)in)REC L)in)REC
GPR174 L)in)REC H)in)REC
ITM2A H)in)REC L)in)REC
LINC00707 H)in)REC L)in)REC
LINC01609 H)in)REC L)in)REC
LOC101927502 H)in)REC L)in)REC
LRP1B L)in)REC L)in)REC
NKAIN2 H)in)REC L)in)REC
NRXN3 L)in)REC L)in)REC
OPCML L)in)REC L)in)REC
RBFOX1 L)in)REC L)in)REC
SORCS3 H)in)REC L)in)REC
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Several observations were made following this exercise. First, the data confirmed that 
many gene transcripts showed altered expression levels following R-CHOP treatment and 
relapse, and that the pattern of changes in the expression levels was different in each case. 
Second, many of the altered transcripts coded for cell components and pathways that are already 
known to be important for oncogenesis in DLBL and other types of neoplasms. Third, some 
pathways found to be altered following treatment in this study have not yet been described as 
important markers in lymphoma. This new finding may provide important new insights into 
personalize treatment of DLBL.  
 To extend the proof-of-feasibility exercise, Case 1 was subjected to additional analysis by 
selecting one high-yield pathway, which I performed literature searches to determine whether 
specific components of this pathway could be potential targets for therapies with drugs that are 
already available, or in development.  For this exercise, the cytokine pathway was chosen, as it is 
known to have significance for the pathogenesis of lymphoma, but has not been discussed 
seriously in most literatures in the context of targeted lymphoma therapies. This exercise 
required a review of  cytokine pathways in general, with specific attention paid to the roles of 
proteins  encoded by genes that had been shown to have altered expressions in the RNASeq 
analysis of the post-therapy sample in Case 1.  
 Cytokines are soluble, extracellular small proteins or glycoproteins. They can be grouped 
into different families, including; chemokines, interferons, interleukins, lymphokines, and tumor 
necrosis factors. Cytokines are secreted by a broad range of cells in the body. Any given 
cytokine can be secreted from more than one type of cell, and any one function may be 
performed by more than one cytokine.  They have important roles in fighting infections and other 
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pathologies, usually by regulating cells’ responses for innate and adaptive inflammatory immune 
responses. Cytokines are also involved in cell differentiation, growth, repair, death, and tissue 
angiogenesis. They are usually activated by a stimulus, and exert their action by binding to 
specific receptors on the surface of their target cells.  
 Normal B-cell development and maturation relies on well-regulated interactions with 
other immune cells and stromal cells.  Interactions between lymphoma cells with their 
microenvironment are also essential for cancer development and metastasis.[9] Tumor 
microenvironment components are not only part of the body’s antitumor inflammatory response, 
but they also play a critical role in enabling cancer progression[10]. Cytokines and their 
receptors facilitate the crosstalk between normal and neoplastic cells, and the presence of 
cytokines in the tumor microenvironment contributes to cancer pathogenesis[11]. In addition, 
compelling epidemiological data shows that unsolved body immune reactions, specifically 
diverse forms of chronic inflammation, promote malignant transformation and cancer 
development[11]. Cancer cells use host derived cytokines that normally function to promote 
growth, constrict apoptosis and assist with invasion and metastasis to their advantage.  
 Since lymphoma cells are immune cells, they co-opt the trafficking and homing of 
normal immune cells to locate a supportive environment for their growth. Lymphoma cells 
express cytokine receptors, and the pattern of expression of these receptors correlate with the site 
of their metastasis. Chemokine receptors CCR7, CXCR4 and CXCR5 are involved in homing 
and trafficking within lymph nodes, and it has been observed that they are highly expressed on 
lymphoma subtypes with widespread nodal metastasis.  These receptors are less expressed on 
lymphoma subtypes that remain localized.[10] Cytokines-cytokine receptor pathway components 
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represent an attractive promising target in oncology therapeutics, and are currently a hot topic in 
clinical trials. 
The following discussion focuses on cellular functions of mRNAs that showed increased 
expression following therapy in Case 1, of which components were identified by DAVID tool. 
Current data suggests that any or all of these cytokines/cytokine receptors could be potential 
targets for directed personalized therapies. 
 
C-C Motif Chemokine Ligand 19 (CCL19): showed (8.5)-fold higher expression in the 
recurrence sample (in relative to ABL1 gene) than in the initial sample: 
 
CCL19 is a homeostatic chemokine, it is expressed in the secondary lymphoid organs. It 
regulates lymphoid cells, and has a role in Dendritic cells (DCs) homing. It could promote 
inflammation, and it has been associated in various inflammatory diseases and infectious 
disorders. Its receptor is CCR7.[12] 
CC cytokines fall under the chemokine superfamily, which is further classified into 
subgroups, CC, CXC, CX3C and C. Members of this super family promote cytoskeleton 
rearrangement, adhesion to endothelial cells, and directional migration, with involvement in 
many different stages of tumor development including initiation, growth, and progression.[13] It 
has been previously reported that this system can be hijacked by epithelial cancer cells and may 
facilitate the dissemination of tumor cells. Chemokines and their receptors have also been 
identified as possible contributors to the metastatic process[14], and many studies have shown 
that CCL19 increases cell proliferation in many different cancers.[13]  
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DCs play an essential role in the initiation and regulation of antigen specific immune 
responses, and they have the ability to initiate antitumor immune responses. Upon encountering 
antigens, immature DCs take these antigens and process them. They then undergo a maturation 
process with expression of CCR7, which directs these cells toward their ligands CCL19 or 
CCL21. These ligands are usually present in T-cell enriched areas in the secondary lymphoid 
organs. Once DCs present the processed antigens to T-cells, they start to differentiate and attack 
their targets.[15] In many different cancers, the DCs have impaired maturation, leading to 
decreased stimulatory effects on T-cells. Hwang et al.[15] conducted a study using a single cell-
based analysis in a 3D microfluidic device on several breast cancer cell lines. They observed that 
breast cancer cells release soluble factors, increasing CCL19-induced directional persistence of 
DCs. The triple negative breast cancer cells facilitated this movement by upregulating the JNK/c-
Jun signaling pathway. They also noticed that triple negative breast cancer cells upregulated DCs 
secretion of pro-inflammatory cytokines. When T-cells are induced by DCs, they become 
extremely proliferative and resistant to activation of induced cell death, and their secretion of 
pro-inflammatory cytokines increased. The high levels of pro-inflammatory cytokines may result 
in creating a host inflammatory environment which may promote tumor growth.  
 
C-X-C Motif Chemokine Ligand 12 (CXCL12): showed (12.11)-fold higher expression in 
the recurrence sample (In relative to ABL1 gene) than the initial sample: 
CXCL12 (also called SDF-1) binds to its receptor CXCR4, the downstream effects of this 
activation ultimately affect many cellular functions including inflammation response, tumor 
progression, metastasis, vasculogenesis, and the mobilization of hematopoietic stem cells. [16] 
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CXCL12 is crucial for normal B-cell growth, and it is expressed in normal tissues and 
serum. It is also expressed by stem cells, endothelial cells, multiple immune cells, stromal 
fibroblasts, and cancer cells. Levels of CXCL12/CXCR4 were reported high in patients with 
many solid tumor types such as breast, gastric, pancreatic, ovarian, cervical, and carcinoma of 
the oral cavity. Furthermore, CXCL12/CXCR4 levels were higher in patients with advanced 
stages of the B-cell neoplasm chronic lymphoblastic leukemia patients (CLL) than in patients 
with lower stages. CXCL12/ CXCR4 can affect cancer by two mechanisms: CXCL12 can exert a 
direct autocrine effect enhancing cancer cell progression and angiogenesis; and it can also attract 
cancer cells expressing CXCR4 to CXC12-expressing organs to initiate metastasis in those 
organs.  Guo et al.[17] has suggested that CXCL12 can activate the NFκB pathway, which can 
suppress apoptosis. CXCR4-positive inflammatory, vascular and stromal cells can be attracted to 
the tumor mass if the tumor had high levels of CXCL12. These cells then release growth factors, 
cytokines, chemokines and pro-angiogenic factors providing the perfect microenvironment for 
cancer development.  
In Case 1 recurrence sample, high expression of CXCL12 and other cytokines and their 
receptors were observed. Components of the NFκB pathway were also identified by DAVIDS 
tool to be significantly upregulated in this case. These observations are consistent with those of 
Guo et al.[17]  
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C-X-C Motif Chemokine Ligand 13 (CXCL13): it had (9.1)-fold higher expression in the 
recurrence sample (in relative to ABL1 gene) than the initial sample: 
CXCL13 is a B-cell chemoattractant and it is highly expressed in secondary lymphoid organs by 
T-follicular helper cells, DCs, and stromal cells. It promotes the migration and mobility of B-
cells, which express its receptor CXCR5.[18] 
 In a study of breast cancer patients, high expression of CXCL13 was associated with poor 
prognosis[19]. Singh et al.[20] reported significantly elevated levels of CXCL13 in the serum of 
prostate cancer patients compared to normal healthy donors, benign prostatic hyperplasia, and 
high-grade prostatic intraepithelial neoplasia. They also reported that CXCL13 was a better 
predictor of prostate cancer than prostate-specific antigen. CXCL13 and CXCR5 high expression 
was also correlated with the development, metastasis, and recurrence of colon cancer[21].  
Rubenstein et al.[22] conducted a study to compare the levels of CXCL13 and IL-10 in central 
nervous system fluid from lymphoma patients and those with inflammatory and degenerative 
neurologic diseases.  Increased levels of CXCL13 and IL-10 were specific for primary and 
secondary central nervous system lymphoma, and associated with poor outcome. Thus, the 
authors suggested the use of CXCL13 and IL-10 as a diagnostic marker in primary CNS 
lymphoma.  
 
Tumor Necrosis Factor Ligand Superfamily Member 7 (CD70): it had (15.6)-fold higher 
expression in the recurrence sample (in relative to ABL1 gene) than the initial sample: 
CD70 is a cytokine that falls under the tumor necrosis factor (TNF) ligand family and 
binds to its receptor CD27. This binding plays an important role in immune regulation. It is 
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solely expressed and regulated upon immune activation by an antigen. It is expressed on 
activated DCs, B, T-cells, and natural killer (NK) cells. CD70 is required by epithelial and other 
cell types during malignant transformation. [23] 
Normally, CD70 activates the NFκB and c-Jun kinase pathways upon binding to its 
receptor CD27. The cytoplasmic residues of CD27 then bind to TNF receptor-associated factors 
such as TRAF2 and TRAF5, ultimately leading to proliferation, differentiation, and survival.  
CD70 expression has been reported in both hematological and solid tumors; in particular, in 
lymphomas, renal cell carcinoma, nasopharyngeal carcinoma, and Epstein–Barr virus-induced 
carcinomas. High expression of CD70 in B-cell lymphoma, renal cell carcinoma, and breast 
cancer is associated with poor prognosis. CD70 is expressed in the primary tumors, and up to 
100% stable expression of CD70 is found in metastatic patient-derived tissues. Aberrant 
epigenetic of the CD70 promotor region primarily demethylation has been associated with 
constitutive expression of CD70 in large B cell lymphoma. [24] 
Recently, CD70 and CD27 have emerged as valuable targets for immunotherapy.  
 
TNF Receptor Superfamily Member 21(TNFRSF21): it had (19.4)-fold higher expression in 
the recurrence sample (in relative to ABL1 gene) than the initial sample: 
TNFRSF21 also called death receptor 6 (DR6) is a member of the death receptor family, 
which belongs to the tumor necrosis factor receptors super family. This receptor has the ability to 
induce apoptosis by activating the NFκB pathway and the mitogen-activated protein kinase 8. 
DR6 is expressed in many tissues but with higher expression in lymphoid organs, heart, brain 
and pancreas. it plays a role in regulating immune responses. [25] 
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The mechanism of action of TNFRSF21 is still not fully understood and its ligand is still 
unknown. However, it is known that TNFRSF21 consists of two domains, an extracellular 
cysteine rich domain and an intracellular death domain that induces apoptosis. High levels of 
TNFRSF21 have been observed in the late stage ovarian cancer, prostate cancer, breast cancer 
and a variety of solid tumor cell lines. [26],[27],[25]  
 Yang et al.[26] demonstrated that TNFRSF21 can have a role in either cancer cell 
survival or death, depending on the microenvironmental conditions. They also suggested that 
TNFRSF21 has a potential role in the tumor microenvironment enhancing angiogenesis and 
facilitating tumor growth. Upon knocking down TNFRSF21 in mouse melanoma, tumor growth 
was inhibited by suppressing the expression of VEGF-A, PDGF-β, VEGF-D and PDGFR-α 
(blood vessel formation related factors).  
 
Interleukin-10 (IL-10): it had (8.4)-fold higher expression in the recurrence sample  
(in relative to ABL1 gene) than the initial sample: 
IL-10 is an anti-inflammatory cytokine, it plays an important role in the regulation of 
immune responses, and preventing autoimmune diseases. It is widely expressed by both innate 
and adaptive immune system cells.[28]  
 
 IL-10 expression may be regulated pre-and/or post-transcription. The role of IL-10 in 
cancer development and progression is controversial but multiple studies have reported a direct 
correlation between IL-10 expression in serum or tumor and poor patient prognosis. Cancer cells 
may express IL-10 to escape the immune surveillance. If the cancerous cells expressed IL-10R, 
the production of IL-10 in the tumor microenvirmoent will mainly act as cancer development 
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promotor. The ability of IL-10 to downregulate MHC II in tumor cells provides an 
immunosuppressive environment facilitating tumor escape from the immune system. Other 
studies found that IL-10 had antitumor activity by stimulating NK-cells and cytotoxic T-cells to 
kill cancer cells. The presence of other cytokines in the microenvironment can affect IL-10 
function and its positive or negative effects on cancer progression.[29]  
 
IL-6 Receptor Subunit Alpha (IL6R): it had (10.5)-fold higher expression in the recurrence 
sample (in relative to ABL1 gene) than the initial sample: 
It belongs to class I cytokine receptor family. It is a multi-chain receptor complex. It has 
ligand binding components and signal transduction components. The ligand binding part can be 
found in both soluble or membraned bounded forms, while the signal transduction part is a 
glycoprotein.[30]  
When IL-6 binds to IL-6R family members, any or all of the JAK–STAT, MAPK, PI3K 
pathways are activated, ultimately causing changes in the transcription of genes involved in 
proliferation (c-MYC, cyclin D1), angiogenesis (VEGF, notch3), metastasis (MMP9, CXCR4, 
CXCL12), chemoresistance (MDR1, GSTpi) and survival (Bcl-2, Mcl-1).[31]  
 
Interleukin 7 Receptor (IL7R): it had (8.1)-fold higher expression in the recurrence sample 
(in relative to ABL1 gene) than the initial sample: 
IL-7 binds to its receptor IL-7R generating essential signals for normal T-cell 
development and homeostasis.  Zenatti et al. [32] reported that IL7R mutations play an important 
role in tumor formation and progression. It has specially an active role in T-cell leukemogenesis.  
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Pro-tumor effects of IL-7 and its receptor are thought to occur by preventing apoptosis. A 
study suggested that IL-7 and its receptor upregulates cyclin D1 and Bcl-2, decreases P53 and 
BCL2 associated X protein. IL-7 may increase proliferation and lymphovascular formation. It 
has been reported as an oncogene in T-cell acute lymphoblastic leukemia.[33]  
 
Lymphotoxin Alpha (LTα): it had (8)-fold higher expression in the recurrence sample (in 
relative to ABL1 gene) than the initial sample: 
LTα previously known as TNFβ, belongs to the TNF family. It is a soluble homotrimer 
that can attach to the cell surface only when forms heterotrimers with lymphotoxin beta. It is 
structurally similar to TNFα. It exerts its biological function by binding to its receptors TNFR1 
and TNFR2. It is expressed by CD4+ T helper type 1, CD8+ T cells, NK cells, B cells, and 
macrophages. It has a role in lymphoid organ development, immune system function, 
inflammation, host defense, and maintenance of lymphoid microenvironment. Previous studies 
reporting the functions of this cytokine used mice lack LTα gene, and the applicability of LTα 
roles in human is less clear. [34] 
 
TNF Superfamily Member 12 (TNFSF12): it had (20.9)-fold higher expression in the 
recurrence sample (in relative to ABL1 gene) than the initial sample: 
TNFSF12 is also known as TWEAK and it is a ligand for FN14/TWEAKR.  It has a role 
in numerous cellular activities involving differentiation, migration, proliferation, inflammation, 
angiogenesis, and apoptosis. It is expressed as a transmembrane protein, then it is proteolytically 
cleaved into the soluble active cytokine. TWEAKR can be found in various tissues, it is highly 
expressed in the context of injury and tissue regeneration.[35]  
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 Studies have shown that both TNFSF12 and its receptor have high expression in 
inflammatory cells and cancer cells. The cellular activities promoted by TNFSF12, including cell 
survival, migration, angiogenesis, proliferation, and differentiation inhibition, are linked to 
tumorigenesis.[36]  
 
In summary, published data indicate that cytokine pathways in general may be targets for 
manipulation in many different forms of cancers, including B-cell lymphomas. There is also 
evidence in literatures that the specific components of the pathways identified as up-regulated 
following therapy in Case 1 would be worth investigation as possible targets of directed therapy 
in this specific DLBL. If the methods used in this study were to be clinically useful, however, 
directed therapies for these specific components discussed above or other components of the 
pathways identified as altered in this sample, would need to be clinically available. To gain some 
insights into this aspect, some of currently available drugs targeting the cytokine pathway are 
shown in Table 4. Since the levels of mRNA of these potential target genes are upregulated by 
five-folds or more in Case 1, these drugs, singly or in combination, can be effective against 
DLBL.  
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Table 4: Potential targeted therapies available for components of the cytokine pathway(s). mAb 
denotes monoclonal antibody. 
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Gene Drug Phase Mechanism Reference 
CXCL13 MAb5261 Preclinical • mAb* 
• Blocks CXCL13 
Klimatcheva E et al. BMC 
Immunology 2015;16:6.[37] 
CD70 SGN-
CD70A 
Phase I 
trials 
• mAb-toxin conjugate 
• Binds CD70 & 
internalized toxin inhibits 
DNA replication 
Jacobs J et al. Pharmacology and 
Therapeutics 2015;155:1-10.[38] 
 AMG 172  
Ph
ase I trials 
• mAb-toxin conjugate 
• binds CD70 & 
internalized toxin disrupt 
microtubules 
Jacobs J et al. Pharmacology and 
Therapeutics 2015;155:1-10.[38] 
 ARGX-110 Phase I 
trials 
• mAb 
• Neutralizes CD70 
• Allows Ab-dependent 
complement toxicity and 
phagocytosis 
Jacobs J et al. Pharmacology and 
Therapeutics 2015;155:1-10.[38] 
IL10 B-N10 Preclinical • mAb 
• Neutralizes IL-10 
Llorente L et al. Arthritis and 
Rheumatism 2000;43:1790-1800[39] 
IL-6R Tocilizumab Approved • mAb 
• Inhibits binding of IL-6 
to IL-6R 
Hunter C and Jones S. Nature 
Immunology 2015;16:448-457.[40] 
 Sarilumab Approved • mAb 
• Inhibits IL-6R 
Hunter C and Jones S. Nature 
Immunology 2015;16:448-457.[40] 
 Siltuximab Approved • mAb 
• Inhibits binding of IL-6R 
Hunter C and Jones S. Nature 
Immunology 2015;16:448-457. 
2015.[40] 
IL-7R OSE-127 Preclinical • mAb 
• Inhibits IL-7R 
http://ose-immune.com/en/portefeuille-
de-produits/effi-7/ 
TNFSF12 RG7212 Phase I 
trials 
• mAb 
• Inhibits TNFSF12 
Cheng E et al. Frontiers in 
Immunology 2013;4:1-13.[41] 
 PDL192 Phase I 
trials 
• mAb 
• targets fn14 (TNFSF12 
receptor) 
Cheng E et al. Frontiers in 
Immunology 2013;4:1-13.[41] 
 Fn14-
TRAIL 
Preclinical • Fn14-TRAIL chimeric 
molecule 
• Blocks TNFSF12 
Cheng E et al. Frontiers in 
Immunology 2013;4:1-13.[41] 
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Discussion, Conclusion, and future work 
 
Through the work presented here, all three goals established at the on-set of this project 
have been achieved as described below: 
1.   An RNASeq method that can achieve "clinical-grade" transcriptome analysis has been 
identified. 
2.   The RNASeq method was used successfully to classify patients with DLBL into correct 
subgroups of clinical prognostic categories as defined by prior "gold-standard" RNA 
transcription studies using “research-grade” techniques.  
3.   A proof of feasibility study has been successfully carried out to prove the concept that 
this RNASeq method can identify mRNA transcripts that are significantly altered post-
therapy relapse in DLBL. Furthermore, publicly available analysis tools can be used to 
demonstrate how the corresponding proteins may be important for functions in normal 
and neoplastic cell systems so that promising targets for individualized therapy can be 
identified. Published data support this conclusion as pharmaceuticals that are capable of 
altering components of the pathways identified by this study with patient’s samples have 
also previously identified by other methods such as nucleotide microarrays and gene 
expression analysis by RT-PCR. Since these pharmaceuticals are already available to use 
at clinics, their efficacy and specificity associated with biomarkers identified by this 
study may be examined in a clinical setting.  
 
Clearly, the work presented here is only preliminary. However, this type of proof of 
feasibility study is a critically important step toward the ultimate goal of truly individualized 
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cancer therapy. As far as I know, no similar study has thus far been published in the scientific or 
clinical literatures. Many studies have evaluated groups of DLBL samples either at the diagnostic 
or after therapy stage, but studies reporting a detailed investigation at individual neoplasms at 
pre-and post-therapy stage appear absent. The importance of this approach (investigating 
individual neoplasms at pre-and post-therapy) was reinforced by the encouraging data shown in 
this study. Although several intracellular pathways may be altered post-therapy in most cases, 
each individual patient showed also a unique combination of altered pathways or components in 
the single pathway. In addition, I have also identified, several alterations in pathway components 
that have not yet been identified as important in DLBL, but are being investigated in other types 
of neoplasms and were reported to have a diagnostic or prognostic values such as TNFRSF21, 
TNFSF12, CCL19, and some other components of different pathways. 
 As discussed in the introduction, previous studies on DLBL transcriptomes have been 
carried out using oligonucleotide arrays containing pre-selected targets based on prior knowledge 
of pathways thought to be relevant to lymphoma. Other studies used similar pre-selected panels 
for some relevant genes. The technology in the current study differs from prior work in at least 
two ways, which can be advantageous for clinical use:  
1.   The entire transcriptome (all known coding gene products) are theoretically detectable 
using the Illumina assay, so the detection of transcripts is not restricted to a subset 
already described in the literature. This should allow for the detection of transcripts and 
pathways that may be altered and have not been previously identified in drug-
resistant/recurrent DLBL.  
2.   While prior studies used oligonucleotide arrays to capture targeted mRNAs, the Illumina 
method uses sequencing of mRNA to detect the transcripts that are present. High-
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throughput sequencing is a more powerful technology than oligonucleotide arrays, not 
only because it is less restrictive (as discussed above) but also because it is more flexible. 
In addition, it can be done using very small amounts of RNA and it is cost effective for 
routine use. Above all, the utility of this method has been “verified” by results obtained 
from clinical and oligo array-based studies.  
 
 Although adoption of high-throughput sequencing technology has been rapid and is 
generating a wealth of basic cell biological data, the development of databases and software to 
store and access this data in a useful manner has lagged behind. Only recently have these tools 
been available, and it is necessary to determine if they are sufficiently developed to make the 
approach piloted in this small study feasible for clinical use. The experience obtained during this 
study suggests that most products are still quite primitive with respect to the amount of 
information contained, and quite "clunky" with respect to the ease of use for the purpose 
required. However, these vast amounts of data/information should eventually be useful for 
practical purposes, and this aspect moves forward very rapidly. The work described in this thesis 
is part of this effort, and has clearly demonstrated that the analysis of transcriptome with high 
throughput RNAseq-based study is feasible to identify potentially disrupted cellular pathways 
that can eventually lead to the development of therapeutic targets for each individual cancer 
patient. Thus, it was concluded that this feasibility study project was successful, and that it is 
worth continuing to pursue this approach using DLBL as a model. 
 A more in-depth study on this project has been limited due to the short time-frame and 
insufficient research budget. Assuming these limitations can be addressed, the following work 
may be considered to furthering this work: 
47 
 
1.   Further ensurance of the reproducibility of the RNASeq method would be needed. 
Although my data generated using relatively small number of samples appear to be 
reproducible, more samples and more extensive evaluation of the transcript variations 
may be needed to further ensure the reliability of data. 
2.   More work is needed to determine if the sensitivity of the transcript detection is adequate 
for the most clinically relevant transcripts and that their alterations are relevant to tumor 
development, progression, resistant to therapies, and the use of appropriate therapies. It 
has been suggested that some of the most important transcripts are found at very low 
levels; therefore, it may be difficult to detect unless a highly sensitive method is used. 
The sensitivity of the assay was not systematically examined in this project. Further 
refinement may be needed to obtain truly reliable data.  
3.   It would be useful to evaluate and normalize the sequencing data using different 
algorithms, not only one, as done in this study. There are several published algorithms 
that maybe considered to use in the future, such as culling of reads and using different 
read normalization methods as mentioned in Li et al.[42] 
4.   Evaluation of significantly altered transcripts could be greatly expanded. In this study, 
only those transcripts that showed at least 5× alterations in mRNA levels, and only a 
single pathway in one case (Case 1) has been evaluated in detail. Many studies have 
suggested that alterations as low as 2× could be significant and that transcript sets, albeit 
large, may be clinically relevant. It may be also possible to evaluate for only those 
transcripts that are even more substantially altered (e.g. 10×) to identify truly significant 
alterations that are directly relevant to the clinical setting. In any cases, the manual 
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process used in this study is very labor intensive and future work should be streamlined 
by development of an automated algorithm.  
5.   It would have been interesting to more extensively compare the data obtained with prior 
transcriptome analyses of DLBL patients with respect to known, biologically and 
clinically relevant subgroups. Although this was not the primary goal of this project, the 
ability to stratify DLBL at the time of diagnosis into relevant prognostic subgroups using 
the current “gold-standard" RNA evaluation approach has been elusive for clinical 
laboratories. It would be exciting to extend this work into a true validation of this type for 
clinical assay development.  
6.   Much more time could be spent evaluating the data using tools designed to identify 
clinical relevance of the transcripts showing significant alterations following therapy. 
There are more tools available, each with advantages and disadvantages, and finding the 
correct combinations of tools and building an algorithm that could be validated for real 
clinical use would be a large project in itself.  
7.   The testing of potential targeted therapies using an in vitro system would be a critical 
next step toward proving feasibility of this approach to individualized medicine. 
Although the time frame of this project did not allow for prospective collection of fresh 
diagnosis/recurrence sample pairs that could be stored as viable cells for later studies, this 
type of tissue would be useful. The goal would be to perform the RNASeq transcriptome 
experiment as done in this project on both samples, and then develop a system through 
which these cells could be grown in vitro (or in animals) long enough to carry out 
experiments to determine the most effective therapies. Although this can be challenging, 
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it is certainly doable. If successful, the outcome of cancer therapy can be dramatically 
improved. 
8.   The analysis of the cytokines pathway showed that these cytokines and their receptors 
play an important role in DLBL relapse. chronic prolonged inflammation promotes 
cancer progression and make it more resistance to therapy. The components of this 
pathway and their effects were studied in other types of cancer, but they weren’t 
sufficiently studied in DLBL since it’s a cancer of immune cells and the inflammation 
was considered a normal result of the stress of the immune cells. The already available 
drugs which target some of these cytokines and their receptors were developed in studies 
considering other types of cancer, it is worthwhile studying them in DLBL in-vivo and 
in-vetro models. 
9.   This type of studies has a great impact on the clinical management. If a low-cost, reliable 
sequencing method was developed and routinely practiced in the clinics, it will increase 
the accuracy of the diagnoses and prognosis, increases the cure rates, and it will reduce 
the costs of the diagnostic tests. It will also eliminate the unnecessary use of the 
expensive and toxic chemo agents that might harm the patients instead of curing them. 
These studies are important to lay the foundation for the development of personalized 
medicine and they increase the pace of the movement towards it.  
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Figures and legends 
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Figure 1: MinION: Oxford Nanopore’s “3rd generation” Sequencer. (1, 2) Protein nanopores are 
embedded in the membrane. (3, 4) A current passes through the pore, making a voltage across 
the membrane. As analyte passes through the pore, there is a characteristic disruption of current 
that can be measured, and the signature used to identify what nucleotide is passing through the 
pore (DNA base, or RNA base). The entire array is embedded in a “stick” that can be inserted 
into any computer following the run for direct analysis.  
Image source: John MacNeill, http://www2.technologyreview.com/article/427677/nanopore-sequencing 
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Figure 2a: Illumina Sequencing Technology workflow. (1): A library of DNA is created (typically 
via targeted PCR or fragmentation) and Illumina sequencing "ends" attached to each fragment. (2): 
Each fragment is secured to flow cell in a unique location via attachment to stationary 
oligonucleotide (primer) with sequencing homology to one of the sequencing ends on each 
fragment. (3, 6): A technique called bridge amplification allows for amplification of each fragment 
into a cluster of identical fragments at each flow cell location, as is required to obtain sufficient 
signal for detection during the sequencing reaction steps. (https://www.illumina.com/). 
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Figure 2b: Illumina sequencing technology workflow. Sequencing is performed by cycling of 
fluorescently labeled basis (one color per base, one base per flow) onto the flow cell. The 
sequencing occurs from the top of each fragment down, with base binding, if complementary on 
each cycle. In each cycle, a camera under the flow cell detects whether binding has occurred in 
each location and if so, knows which base bound, based on which nucleotide is being flowed in the 
cycle. After each cycle, the nucleotide is washed off and the next nucleotide flooded onto the 
array. (https://www.illumina.com/). 
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Figure 3: Sequencing read preparation and normalization flow-chart, explained in detail in the 
Materials and Methods section. 
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Figure 4: RNAseq Illumina method evaluation using 2 samples stored as fresh frozen and FFPE. 
Green color represents upregulated genes, red color represents downregulated genes, black no 
change in relative to ABL1 gene. Sample 1 represents the same tumor in both storage conditions at 
diagnosis, sample 2 represents the same tumor in both storage conditions after therapy relapse. The 
numbers on the right-hand side of the graph represent normalized gene expression (fold change in 
relative to ABL1). Values above 10 are also possible, the legend is to cap the color scale (any 
values above 10 or below -10 are assigned the same color as 10 and -10 respectively). 
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Figure 5: RNAseq full transcriptome analysis of 7 pre-treatment samples of DLBL. Green color 
represents upregulated genes, red color represents downregulated genes, black no change in relative to 
ABL1. 
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Sample 1(1387)    Sample 2(6100)       Sample 3(1009)     Sample 4(2093)   Sample 5(706)       Sample 6(13084)    Sample 7(948) 
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Figure 6a: “Cured & fatal/refractory” grouping. Individual cases in this study are represented in 
columns and genes in rows, with colors representing high (red) or low (black) expression. DLBL 
samples interpreted as falling into the “cured” group show higher expression of the genes in the 
upper panel while DLBL samples interpreted as falling into the “fatal/ refractory’ group show 
higher expression of genes in the lower panel. (Shipp et al. Nature 2002;8;68) 
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Figure 6b: RNA transcripts from genes listed in figure 6a. The genes represented in the RNAseq data 
from each pre-therapy at initial diagnosis sample are shown in rows aligned top to bottom as in 
figure 6a. Each sample would be classified as “fatal/refractory”. Gene names are on the left side. 
Sample names are at the bottom. Note: there are 8 samples as 1-8948-INI sample represents the fresh 
frozen storage condition and 1-948 represents the FFPE storage condition for the sample from the 
same patient at diagnosis. The numbers on the right side represent the number of reads per kb of 
transcript over ABL1. Colors representing high (red) or low (black) expression. 
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Figure 7a: DLBL sample 1 - RNAseq full transcriptome analysis heat map, pre-therapy at initial 
diagnosis sample (left) and after therapy relapse sample (right). After aligning the genes to the 
reference transcriptome, then normalization, heatmaps were generated using gnuplot 5.0. 
patchlevel 6. Green color represents upregulated genes, red color represents downregulated 
genes, black no change in relative to ABL1. The numbers on the right-hand side of the graph 
represent normalized gene expression (fold change in relative to ABL1). Values above 10 are 
also possible, the legend is to cap the color scale (any values above 10 or below -10 are assigned 
the same color as 10 and -10 respectively). 
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Figure 7b: DLBL sample 2 - RNAseq full transcriptome analysis heatmap, pre-therapy at initial 
diagnosis sample (left) and after therapy relapse sample (right). After aligning the genes to the 
reference transcriptome, then normalization, heatmaps generated using gnuplot 5.0. patchlevel 6. 
Green color represents upregulated genes, red color represents downregulated genes, black no 
change in relative to ABL1. The numbers on the right-hand side of the graph represent normalized 
gene expression (fold change in relative to ABL1). Values above 10 are also possible, the legend is 
to cap the color scale (any values above 10 or below -10 are assigned the same color as 10 and -10 
respectively). 
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Figure 7c: DLBL sample 3 - RNAseq full transcriptome analysis heatmap, pre-therapy at initial 
diagnosis sample (left) and after therapy relapse sample (right). After aligning the genes to the 
reference transcriptome, then normalization, heatmaps generated using gnuplot 5.0. patchlevel 6. 
Green color represents upregulated genes, red color represents downregulated genes, black no 
change in relative to ABL1. The numbers on the right-hand side of the graph represent normalized 
gene expression (fold change in relative to ABL1). Values above 10 are also possible, the legend is 
to cap the color scale (any values above 10 or below -10 are assigned the same color as 10 and -10 
respectively). 
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Figure 7d: DLBL sample 4 - RNAseq full transcriptome analysis heatmap, pre-therapy at initial 
diagnosis sample (left) and after therapy relapse sample (right). After aligning the genes to the 
reference transcriptome, then normalization, heatmaps generated using gnuplot 5.0. patchlevel 6. 
Green color represents upregulated genes, red color represents downregulated genes, black no 
change in relative to ABL1. The numbers on the right-hand side of the graph represent normalized 
gene expression (fold change in relative to ABL1). Values above 10 are also possible, the legend is 
to cap the color scale (any values above 10 or below -10 are assigned the same color as 10 and -10 
respectively). 
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Figure 7e: DLBL sample 5 - RNAseq full transcriptome analysis heatmap, pre-therapy at initial 
diagnosis sample (left) and after therapy relapse sample (right). After aligning the genes to the 
reference transcriptome, then normalization, heatmaps generated using gnuplot 5.0. patchlevel 6. 
Green color represents upregulated genes, red color represents downregulated genes, black no 
change in relative to ABL1. The numbers on the right-hand side of the graph represent normalized 
gene expression (fold change in relative to ABL1). Values above 10 are also possible, the legend is 
to cap the color scale (any values above 10 or below -10 are assigned the same color as 10 and -10 
respectively). 
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Figure 7f: DLBL sample 6 - RNAseq full transcriptome analysis heat map, pre-therapy at initial 
diagnosis sample (left) and after therapy relapse sample (right). After aligning the genes to the 
reference transcriptome, then normalization, heatmaps generated using gnuplot 5.0. patchlevel 6. 
Green color represents upregulated genes, red color represents downregulated genes, black no 
change in relative to ABL1. The numbers on the right-hand side of the graph represent 
normalized gene expression (fold change in relative to ABL1). Values above 10 are also possible, 
the legend is to cap the color scale (any values above 10 or below -10 are assigned the same color 
as 10 and -10 respectively). 
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Figure 7g: DLBL sample 7 - RNAseq full transcriptome analysis heat map pre-therapy at initial 
diagnosis sample (left) and after therapy relapse sample (right). After aligning the genes to the 
reference transcriptome, then normalization, heatmaps generated using gnuplot 5.0. patchlevel 6. 
Green color represents upregulated genes, red color represents downregulated genes, black no change 
in relative to ABL1. The numbers on the right-hand side of the graph represent normalized gene 
expression (fold change in relative to ABL1). Values above 10 are also possible, the legend is to cap 
the color scale (any values above 10 or below -10 are assigned the same color as 10 and -10 
respectively). 
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Figure 8a: DLBL sample 1 showing gene expression of genes that changed ≥ 5-fold between pre-
therapy at initial diagnosis sample (left) and after therapy relapse sample (right). After aligning the 
genes to the reference transcriptome, then normalization, heatmaps generated using gnuplot 5.0. 
patchlevel 6. Green color represents upregulated genes, red color represents downregulated genes, 
black no change in relative to ABL1. The numbers on the right-hand side of the graph represent 
normalized gene expression (fold change in relative to ABL1). Values above 10 are also possible, 
the legend is to cap the color scale (any values above 10 or below -10 are assigned the same color as 
10 and -10 respectively). Note: the genes on the left of the figure are also shown in appendix A. 
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Figure 8b: DLBL sample 2 showing gene expression for genes that changed ≥ 5-fold between pre-
therapy at initial diagnosis sample (left) and after therapy relapse sample (right). After aligning the 
genes to the reference transcriptome, then normalization, heatmaps generated using gnuplot 5.0. 
patchlevel 6. Green color represents upregulated genes, red color represents downregulated genes, 
black no change in relative to ABL1. The numbers on the right-hand side of the graph represent 
normalized gene expression (fold change in relative to ABL1). Values above 10 are also possible, the 
legend is to cap the color scale (any values above 10 or below -10 are assigned the same color as 10 
and -10 respectively). Note: the genes on the left of the figure are also shown in appendix A. 
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Figure 8c: DLBL sample 3 showing gene expression for genes that changed ≥ 5-fold between pre-
therapy at initial diagnosis sample (left) and after therapy relapse sample (right). After aligning the 
genes to the reference transcriptome, then normalization, heatmaps generated using gnuplot 5.0. 
patchlevel 6. Green color represents upregulated genes, red color represents downregulated genes, 
black no change in relative to ABL1. The numbers on the right-hand side of the graph represent 
normalized gene expression (fold change in relative to ABL1). Values above 10 are also possible, 
the legend is to cap the color scale (any values above 10 or below -10 are assigned the same color 
as 10 and -10 respectively). Note: the genes on the left of the figure are also shown in appendix A. 
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Figure 8d: DLBL sample 4 showing gene expression for genes that changed ≥ 5-fold between pre-
therapy at initial diagnosis sample (left) and after therapy relapse sample (right). After aligning the 
genes to the reference transcriptome, then normalization, heatmaps generated using gnuplot 5.0. 
patchlevel 6. Green color represents upregulated genes, red color represents downregulated genes, 
black no change in relative to ABL1. The numbers on the right-hand side of the graph represent 
normalized gene expression (fold change in relative to ABL1). Values above 10 are also possible, 
the legend is to cap the color scale (any values above 10 or below -10 are assigned the same color as 
10 and -10 respectively). Note: the genes on the left of the figure are also shown in appendix A. 
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Figure 8e: DLBL sample 5 showing gene expression for genes that changed ≥ 5-fold between pre-
therapy at initial diagnosis sample (left) and after therapy relapse sample (right). After aligning the 
genes to the reference transcriptome, then normalization, heatmaps generated using gnuplot 5.0. 
patchlevel 6. Green color represents upregulated genes, red color represents downregulated genes, 
black no change in relative to ABL1. The numbers on the right-hand side of the graph represent 
normalized gene expression (fold change in relative to ABL1). Values above 10 are also possible, 
the legend is to cap the color scale (any values above 10 or below -10 are assigned the same color 
as 10 and -10 respectively). Note: the genes on the left of the figure are also shown in appendix A. 
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Figure 8f: DLBL sample 6 showing gene expression for genes that changed ≥ 5-fold between pre-
therapy at initial diagnosis sample (left) and after therapy relapse sample (right). After aligning the 
genes to the reference transcriptome, then normalization, heatmaps generated using gnuplot 5.0. 
patchlevel 6. Green color represents upregulated genes, red color represents downregulated genes, 
black no change in relative to ABL1.The numbers on the right-hand side of the graph represent 
normalized gene expression (fold change in relative to ABL1). Values above 10 are also possible, 
the legend is to cap the color scale (any values above 10 or below -10 are assigned the same color 
as 10 and -10 respectively). Note: the genes on the left of the figure are also shown in appendix A. 
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Figure 8-g: DLBL sample 7 showing gene expression for genes that changed ≥ 5-fold between pre-
therapy at initial diagnosis sample (left) and after therapy relapse sample (right). After aligning the 
genes to the reference transcriptome, then normalization, heatmaps generated using gnuplot 5.0. 
patchlevel 6. Green color represents upregulated genes, red color represents downregulated genes, 
black no change in relative to ABL1. The numbers on the right-hand side of the graph represent 
normalized gene expression (fold change in relative to ABL1). Values above 10 are also possible, 
the legend is to cap the color scale (any values above 10 or below -10 are assigned the same color as 
10 and -10 respectively). Note: the genes on the left of the figure are also shown in appendix A. 
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Figure 9a: DLBL sample 1 – Pathway analysis screenshots. Top DAVID’s tool showing the altered 
pathways and the counts (numbers) of altered genes in each pathway (see Table 5, which shows the 
altered genes in each pathway). Bottom Panther tool showing the biological functions of altered 
genes in the sample. Note: Blue stars on the left side in DAVID’s tool screen shot indicates that the 
same pathway is altered in another sample as well.  
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Table 5: Sample 1 altered genes in the pathways identified by DAVID tool, and their expression 
in the recurrence tumor.  
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Pathway  genes expression in recurrence 
Cytokine-cytokine receptor interaction  
CCL19  High 
CXCL12 High 
CXCL13 High 
CD70 High 
CSF2RB High 
CSF2RB High 
IL10 High 
IL6R High 
IL7R High 
LTA High 
TNFSF12 High 
Pathway  genes expression in recurrence 
Complement and coagulation cascades 
 F5  High 
CR2 High 
C4A High 
CSAR1 High 
TFPI High 
Pathway  genes expression in recurrence 
 NF-kappa B signaling pathway 
CCL19  High 
CXCL12 High 
LTA High 
TLR4 High 
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Figure 9b: DLBL sample 2– Pathway analysis screenshots. Top DAVID’s tool showing the 
altered pathways and the counts (numbers) of altered genes in each pathway (see Table 6, which 
shows the altered genes in each pathway). Bottom Panther tool showing the biological functions 
of altered genes in the sample. Note: Blue stars on the left side in DAVID’s tool screen shot 
indicates that the same pathway is altered in another sample as well. 
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Table 6:  Sample 2, altered genes in the pathways identified by DAVID tool, and their expression 
in the recurrence tumor.  
102 
 
 
 
  
Pathway  genes expression in recurrence 
 Extracellular matrix--receptor interaction 
COL11A1 High 
ITGB6 Low 
LAMB3 Low 
LAMB4 Low 
Pathway  genes expression in recurrence 
Focal adhesion 
COL11A1 High 
ITGB6 Low 
LAMB3 Low 
LAMB4 Low 
PAK3 Low 
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Figure 9c: DLBL sample 3– Pathway analysis screenshots. Top DAVID’s tool showing the altered 
pathways and the counts (numbers) of altered genes in each pathway (see Table 7, which shows the 
altered genes in each pathway). Bottom Panther tool showing the biological functions of altered 
genes in the sample. Note: Blue stars on the left side in DAVID’s tool screen shot indicates that the 
same pathway is altered in another sample as well. 
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Table 7: Sample 3, altered genes in the pathways identified by DAVID tool, and their expression 
in the recurrence tumor.  
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Pathway  genes expression in recurrence 
 Cell adhesion molecules (CAMs) 
CD6 Low 
CNTNAP2 Low 
HLA-DOA Low 
NRXN3 Low 
SDC1 High 
Pathway  genes expression in recurrence 
Complement and coagulation cascades 
 F5  Low 
C4A Low 
C7 Low 
Pathway  genes expression in recurrence 
 Hematopoietic cell lineage  
CD3E Low 
FCER2 Low 
IL2RA Low 
Pathway  genes expression in recurrence 
Extracellular matrix-receptor interaction 
COMP Low 
SPP1 High 
SD1 High 
Pathway  genes expression in recurrence 
 NF-kappa B signaling pathway 
CCL21 Low 
CARD11 Low 
ZAP70 Low 
Pathway  genes expression in recurrence 
PI3K-Akt signaling pathway 
COMP Low 
FGF14 Low 
FGFR3 Low 
IL2RA low 
SPP1 High 
Pathway  genes expression in recurrence 
 T-cell receptor signaling pathway 
CD3E Low 
CARD11 Low 
ZAP70 Low 
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Figure 9d: DLBL sample 4– Pathway analysis screenshots. Top DAVID’s tool showing the altered 
pathways and the counts (numbers) of altered genes in each pathway (see Table 8, which shows the 
altered genes in each pathway). Bottom Panther tool showing the biological functions of altered genes in 
the sample. Note: Blue stars on the left side in DAVID’s tool screen shot indicates that the same 
pathway is altered in another sample as well. 
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Table 8: Sample 4, altered genes in the pathways identified by DAVID tool, and their expression 
in the recurrence tumor. 
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Pathway  genes expression in 
recurrence 
Pathway  genes expression in 
recurrence 
  Extracellular matrix--
receptor interaction 
COL1A1 Low Pathways in cancer E2F2 Low 
COL1A2 Low FOS High 
COL3A1 Low JUN High 
COL4A1 Low COL4A
1 
Low 
COL4A2 Low COL4A
2 
Low 
COL5A2 Low EPAS1 Low 
COL6A1 Low FLT3 High 
COL6A2 Low MMP2 Low 
COL6A3 Low VEGFA High 
HSPG2 Low ZBTB1
6 
High 
TNC Low Pathway  genes expression in 
recurrence 
THBS1 Low Complement and 
coagulation cascades 
A2M Low 
VWF Low F13A1 Low 
Pathway  genes expression in 
recurrence 
C1S Low 
 Focal adhesion JUN High C3 Low 
COL1A1 Low VWF Low 
COL1A2 Low Pathway  genes expression in 
recurrence 
COL3A1 Low  E2F2 Low 
COL4A1 Low Bladder cancer MMp2 Low 
COL4A2 Low  THBS1 Low 
COL5A2 Low  VEGFA High 
COL6A1 Low Pathway  genes expression in 
recurrence 
COL6A2 Low Proteoglycans in 
cancer 
DCN Low 
COL6A3 Low FLNA Low 
FLNA Low HSPG2 Low 
TNC Low MMP2 Low 
THBS1 Low THBS1 Low 
VWF Low VEGFA High 
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Pathway  genes expression 
in 
recurrence 
Pathway  genes expression in 
recurrence 
 PI3K-Akt signaling 
pathway 
COL1A1 Low  Platelet activation COL1A1 Low 
COL1A2 Low COL1A2 Low 
COL3A1 Low COL3A1 Low 
COL4A1 Low COL5A2 Low 
COL4A2 Low VWF Low 
COL5A2 Low Pathway  genes expression in 
recurrence 
COL6A1 Low  MAPK signaling 
pathway 
FOS High 
COL6A2 Low JUN High 
COL6A3 Low JUND High 
NR4A1 Low DUSP1 High 
TNCL Low FLNA Low 
THBS1 Low NR4A1 High 
VEGFA Low Pathway  genes expression in 
recurrence 
VWF Low  Renal cell carcinoma JUN High 
Pathway  genes expression 
in 
recurrence 
EPAS1 Low 
 p53 signaling 
pathway 
PMAIP High VEGFA High 
SESN1 High       
THBS1 Low       
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Figure 9e: DLBL sample 5– Pathway analysis screenshots. Top DAVID’s tool showing the altered 
pathways and the counts (numbers) of altered genes in each pathway (see Table 9, which shows the 
altered genes in each pathway). Bottom Panther tool showing the biological functions of altered genes 
in the sample. Note: Blue stars on the left side in DAVID’s tool screen shot indicates that the same 
pathway is altered in another sample as well. 
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Table 9: Sample 5, altered genes in the pathways identified by DAVID tool, and their expression 
in the recurrence tumor. 
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  Pathway  genes expression in recurrence 
 Complement and coagulation cascades 
C2 Low 
C3AR1 Low 
SERPINA1 Low 
Pathway  genes expression in recurrence 
 Cell adhesion molecules (CAMs) 
CD6 Low 
HLA-
DQA2 Low 
SIGLEC1 Low 
Pathway  genes expression in recurrence 
 Phagosome 
CD209 Low 
HLA-
DQA2 High 
THBS1 High 
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Appendix A 
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Genes ≥ 5-fold differentially expressed genes in the recurrence sample compared to the initial 
DLBL sample 1. (H in REC: High in recurrence), (L in REC: Low in recurrence). Actual data are 
shown Figure 8a.  
 
ACTG2 H in REC DCP1B H in REC LGALS1 H in REC RGS2 H in REC 
AKT1S1 H in REC DKFZP434K028 H in REC LILRB2 H in REC RPS27L H in REC 
ALOX5 H in REC DLG2 L in REC LINC00707 H in REC SCARB1 H in REC 
ANTXR1 H in REC DNAJC4 H in REC LINC01609 H in REC SERPINF1 H in REC 
APOC2 H in REC DSC1 H in REC LOC100507388 H in REC SFT2D2 H in REC 
ARAF H in REC ELK2AP H in REC LOC101927502 H in REC SH3TC1 H in REC 
ARID5A H in REC EPHB1 H in REC LTA H in REC SKI H in REC 
ATG2A H in REC EPS8 H in REC LTBP2 H in REC SLC2A4RG H in REC 
ATP5I H in REC ERVV-2 H in REC LUM H in REC SLC44A2 H in REC 
BAX H in REC F5 H in REC MAP1S H in REC SLC9A1 H in REC 
BCL3 H in REC FCRL3 H in REC MEGF8 H in REC SMAD1 H in REC 
BGN H in REC FNDC1 H in REC MERTK H in REC SMPDL3A H in REC 
C10orf55 L in REC FPGS H in REC MIR6748 H in REC SNHG8 H in REC 
C14orf1 H in REC FSTL5 H in REC MIR6775 H in REC SNX9 H in REC 
C22orf15 H in REC FUCA1 H in REC MIR6795 H in REC SORBS3 H in REC 
C4A H in REC FURIN H in REC MIR6833 H in REC SORCS3 H in REC 
C5AR1 H in REC GAA H in REC MIR6881 H in REC SPPL2B H in REC 
C7orf73 H in REC GJA1 H in REC MNDA H in REC SYNGR2 H in REC 
CCDC144CP L in REC GPSM3 H in REC MPDU1 H in REC SYNPO H in REC 
CCL19 H in REC GPX4 H in REC MRPL11 H in REC TCN2 H in REC 
CD70 H in REC GRAMD1C H in REC MTCL1 H in REC TERC H in REC 
CDK5R1 H in REC GSE1 H in REC MUC2 H in REC TFPI H in REC 
CDT1 H in REC H19 H in REC NDUFA3 H in REC TGFBI H in REC 
CETP H in REC HIST1H1E H in REC NFATC1 H in REC THEMIS2 H in REC 
CHIT1 L in REC HIST1H2AC H in REC NID1 H in REC THY1 H in REC 
CHL1 H in REC HIST1H2AG H in REC NKAIN2 H in REC TLR4 H in REC 
CLEC17A H in REC HIST1H2AI H in REC NOC4L H in REC TLR9 H in REC 
CMKLR1 H in REC HIST1H3H H in REC OLFML2B H in REC TMEM109 H in REC 
CNPPD1 H in REC HIST1H3I H in REC PHLPP1 H in REC TMEM129 H in REC 
COBLL1 H in REC HIST1H3J H in REC PLA2G2D H in REC TMEM176A H in REC 
COL6A1 H in REC HIST2H2BA H in REC PLAC8 H in REC TNC H in REC 
COLEC12 H in REC HIST2H3D H in REC PLXNA1 H in REC TNFRSF21 H in REC 
CPT1A H in REC HTR3A H in REC PLXNB2 H in REC TNFSF12 H in REC 
CR2 H in REC IL10 H in REC PLXND1 H in REC TSPAN14 H in REC 
CSF2RB H in REC IL6R H in REC POSTN H in REC UBALD2 H in REC 
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CSTA H in REC IL7R H in REC PREX1 H in REC ULK1 H in REC 
CTB-
113P19.1 H in REC INADL H in REC PTGDS H in REC UNC119 H in REC 
CTTNBP2NL H in REC ITGB2 H in REC PTPRF H in REC UQCR10 H in REC 
CWF19L1 H in REC ITM2A H in REC PVRL1 H in REC ZDHHC18 H in REC 
CXCL12 H in REC KDELR1 H in REC PXDN H in REC ZFP36 H in REC 
CXCL13 H in REC KIF21A H in REC RASSF6 H in REC 
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 Genes ≥ 5-fold differentially expressed genes in the recurrence sample compared to the initial 
DLBL sample 2. (H in REC: High in recurrence), (L in REC: Low in recurrence). Actual data are 
shown Figure 8b. 
  
DEC1 L in REC DYNLL1 L in REC LOC101927502 L in REC RAB31 H in REC 
ABCB1 L in REC EDIL3 L in REC LOC101928942 L in REC RALYL L in REC 
ADARB2 L in REC EFHC2 L in REC LOC101929239 L in REC RBFOX1 L in REC 
ADGRB3 L in REC ELAVL2 L in REC LOC285692 L in REC RNF17 L in REC 
ADGRF5 L in REC EMILIN2 L in REC LOC442028 L in REC ROS1 L in REC 
ADGRL3 L in REC FPGT L in REC LRP1B L in REC SERPINA3 L in REC 
AGBL1 L in REC FRG2 L in REC LSAMP L in REC SFTPB L in REC 
AGPAT9 L in REC GAS2 L in REC LTF L in REC SLC26A4 L in REC 
AK5 L in REC GATC L in REC LYPD4 L in REC SNTG1 L in REC 
AMELX L in REC GOLGA6L1 L in REC MCTP1 L in REC SORCS3 L in REC 
AMOT L in REC GOLGA6L6 L in REC MEGF11 L in REC SVOPL L in REC 
AMPH L in REC GOLGA8EP L in REC MIR125B2 L in REC TKTL1 L in REC 
AMY1A L in REC GPC4 L in REC MIR3612 L in REC TMEM167B L in REC 
ANKRD30B L in REC GPC5 L in REC MIR4450 L in REC TPTE2 L in REC 
APTX H in REC GPD1L L in REC MIR4789 L in REC TRIAP1 L in REC 
AS3MT L in REC GPR174 L in REC MIR6744 H in REC USP44 L in REC 
BCAP29 L in REC GPR85 L in REC MIR943 H in REC ZAN L in REC 
C11orf39 L in REC GRM7 L in REC MME H in REC ZCWPW2 L in REC 
C1orf194 L in REC HMGA2 L in REC MMP1 H in REC ZDHHC11 L in REC 
CACNA2D3 L in REC HTR2C L in REC MSI1 H in REC ZFP36L2 H in REC 
CAMKK1 L in REC HYDIN L in REC MTHFD2P1 H in REC ZPBP L in REC 
CELA2A L in REC ITGB6 L in REC MYOM1 H in REC 
  CELSR2 L in REC ITM2A L in REC NCAPH H in REC 
  CFI L in REC KCNH7 L in REC NINL H in REC 
  CNTNAP5 L in REC KIAA1324 L in REC NKAIN2 L in REC 
  COL11A1 H in REC LAMB3 L in REC NRG1 L in REC 
  COL12A1 H in REC LAMB4 L in REC NRXN3 L in REC 
  COQ5 L in REC LINC00113 L in REC NTN4 L in REC 
  CSK H in REC LINC00707 L in REC NTRK2 L in REC 
  CSMD1 L in REC LINC00824 L in REC OPCML L in REC 
  DEPTOR L in REC LINC01017 L in REC OXSM L in REC 
  DIP2C L in REC LINC01603 L in REC PAK3 L in REC 
  DPP6 L in REC LINC01609 L in REC PCSK5 L in REC 
  DSCAM L in REC LOC101927082 L in REC PDE8B L in REC 
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Genes ≥ 5-fold differentially expressed genes in the recurrence sample compared to the initial 
DLBL sample 3. (H in REC: High in recurrence), (L in REC: Low in recurrence). Actual data are 
shown Figure 8c.  
 
 
	  
 
  
AA06 L in REC IL1RAPL1 L in REC TRIM29 H in REC 
ACY3 H in REC IL2RA L in REC ZAP70 L in REC 
AGBL4 L in REC KCNIP4 L in REC ZNF804A L in REC 
AHNAK2 H in REC KLF5 H in REC FLG H in REC 
APCDD1 H in REC KRT1 H in REC HLA-DOA L in REC 
C4A L in REC KRT10 H in REC IFI44 H in REC 
C7 L in REC KRT17 H in REC IFI44L H in REC 
CARD11 L in REC KRT2 H in REC SPOCK2 L in REC 
CCL21 L in REC KRT5 H in REC SPP1 H in REC 
CD3E L in REC KRT6A H in REC SPTBN2 H in REC 
CD6 L in REC LOC100506585 L in REC TOX2 L in REC 
CDHR1 H in REC LOC100507388 L in REC 
	    CDT1 H in REC LOC101927159 L in REC 
	    CMPK2 H in REC LRP1B L in REC 
	    CNTNAP2 L in REC MAGI2 L in REC 
	    COL17A1 H in REC MIR1203 L in REC 
	    COL7A1 H in REC MIR1205 L in REC 
	    COMP L in REC MIR569 L in REC 
	    CSMD1 L in REC MUC16 L in REC 
	    CTNNA3 L in REC MX1 H in REC 
	    DAB1 L in REC NELL2 L in REC 
	    DMKN H in REC NRXN3 L in REC 
	    DSC3 H in REC OPCML L in REC 
	    DSG1 H in REC PARVG L in REC 
	    DSP H in REC PERP H in REC 
	    EPPK1 H in REC PIM2 L in REC 
	    EVPL H in REC PKP1 H in REC 
	    F5 L in REC PPL H in REC 
	    FAT2 H in REC PVRL1 H in REC 
	    FCER2 L in REC RBFOX1 L in REC 
	    FCMR L in REC SCEL H in REC 
	    FDCSP L in REC SDC1 H in REC 
	    FGF14 L in REC SFN H in REC 
	    FGFR3 H in REC SPINK5 H in REC 
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Genes ≥ 5-fold differentially expressed genes in the recurrence sample compared to the initial 
DLBL sample 4. (H in REC: High in recurrence), (L in REC: Low in recurrence). Actual data are 
shown Figure 8d.  
 
  A2M L in REC FLNA L in REC 
ABI3BP L in REC FLT3 H in REC 
AK4 H in REC FOS H in REC 
ALDOC H in REC FOSB H in REC 
APOD H in REC GPNMB L in REC 
APOE L in REC H1F0 H in REC 
APP L in REC HLA-DRB5 L in REC 
ARRDC3 H in REC HLA-DRB6 L in REC 
BGN L in REC HSPG2 L in REC 
BMF H in REC IGFBP2 H in REC 
C1S L in REC JUN H in REC 
C3 L in REC JUND H in REC 
CD68 L in REC KIF18B L in REC 
CLSPN L in REC LOC101929753 H in REC 
COL12A1 L in REC LYZ L in REC 
COL15A1 L in REC MMP2 L in REC 
COL1A1 L in REC MXRA5 L in REC 
COL1A2 L in REC NR4A1 H in REC 
COL3A1 L in REC NXPH4 H in REC 
COL4A1 L in REC PMAIP1 H in REC 
COL4A2 L in REC PNRC1 H in REC 
COL5A2 L in REC POSTN L in REC 
COL6A1 L in REC PPP1R15A H in REC 
COL6A2 L in REC REXO2 H in REC 
COL6A3 L in REC RGS1 H in REC 
CTB-
113P19.1 L in REC SESN1 H in REC 
CXCL9 L in REC SULF1 L in REC 
DCN L in REC SYN3 L in REC 
DUSP1 H in REC TAGAP H in REC 
E2F2 L in REC THBS1 L in REC 
EGR1 H in REC TMEM132B H in REC 
EPAS1 L in REC TNC L in REC 
F13A1 L in REC VEGFA H in REC 
FBN1 L in REC VWF L in REC 
  
ZBTB16 H in REC 
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Genes ≥ 5-fold differentially expressed genes in the recurrence sample compared to the initial 
DLBL sample 5. (H in REC: High in recurrence), (L in REC: Low in recurrence). Actual data are 
shown Figure 8e.  
 
 
  
ADD2 H in REC HSD11B1 L in REC 
ALDH1A1 L in REC HTR3A L in REC 
ALOX15B L in REC HTRA4 L in REC 
AMICA1 L in REC JCHAIN H in REC 
ANKRD22 L in REC MIR3161 L in REC 
ATRNL1 H in REC MIR3664 H in REC 
BCAS1 H in REC MIR511 L in REC 
C2 L in REC MMP20 L in REC 
C3AR1 L in REC MT1G L in REC 
CAPNS2 L in REC MUC4 H in REC 
CCL18 L in REC MZB1 H in REC 
CCL19 L in REC NXT2 H in REC 
CCRL2 L in REC ORM2 L in REC 
CD209 L in REC PADI2 L in REC 
CD6 L in REC PEG10 H in REC 
CHI3L1 L in REC PLEKHG3 L in REC 
CHIT1 L in REC PMEL L in REC 
CLEC12A L in REC POSTN H in REC 
COL12A1 H in REC PSTPIP2 L in REC 
CPM L in REC RYR1 L in REC 
CTAGE9 H in REC S100A8 L in REC 
CTGF H in REC S100A9 L in REC 
CTNND2 L in REC SCHLAP1 L in REC 
CYP1B1 L in REC SERPINA1 L in REC 
CYR61 H in REC SIGLEC1 L in REC 
DPCR1 L in REC SIGLEC14 L in REC 
DUSP5P1 L in REC SRC L in REC 
FAM171B H in REC SULF1 H in REC 
FMN1 L in REC THBS1 H in REC 
FOXP2 H in REC TLR8 L in REC 
GPR160 H in REC TNFSF13B L in REC 
GPX3 L in REC 
HLA-
DQA2 L in REC 
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Genes ≥ 5-fold differentially expressed genes in the recurrence sample compared to the initial 
DLBL sample 6. (H in REC: High in recurrence), (L in REC: Low in recurrence). Actual data are 
shown Figure 8f.  
 
 
  
CAMK4 H in REC 
COL15A1 L in REC 
COLEC12 H in REC 
FARP1 H in REC 
GPR174 H in REC 
HTR3A H in REC 
LINGO1 H in REC 
MMP9 H in REC 
NRCAM H in REC 
POF1B H in REC 
SLC26A3 H in REC 
SMARCA1 H in REC 
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Genes ≥ 5-fold differentially expressed genes in the recurrence sample compared to the initial 
DLBL sample 7. (H in REC: High in recurrence), (L in REC: Low in recurrence). Actual data are 
shown Figure 8g.  
 
 
 
 
 
 
 
 
 
 
 
 
ATRNL1 H in REC 
CHIT1 L in REC 
CUEDC1 H in REC 
DCC L in REC 
JCHAIN L in REC 
MGMT L in REC 
MS4A1 L in REC 
POSTN H in REC 
SVEP1 L in REC 
